<SEC-DOCUMENT>0001213900-25-090336.txt : 20250923
<SEC-HEADER>0001213900-25-090336.hdr.sgml : 20250923
<ACCEPTANCE-DATETIME>20250923083042
ACCESSION NUMBER:		0001213900-25-090336
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250922
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Unregistered Sales of Equity Securities
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20250923
DATE AS OF CHANGE:		20250923

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Modular Medical, Inc.
		CENTRAL INDEX KEY:			0001074871
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		ORGANIZATION NAME:           	08 Industrial Applications and Services
		EIN:				870620495
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			0331

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41277
		FILM NUMBER:		251331777

	BUSINESS ADDRESS:	
		STREET 1:		10740 THORNMINT ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127
		BUSINESS PHONE:		858-800-3500

	MAIL ADDRESS:	
		STREET 1:		10740 THORNMINT ROAD
		CITY:			SAN DIEGO
		STATE:			CA
		ZIP:			92127

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BEAR LAKE RECREATION INC
		DATE OF NAME CHANGE:	19981208
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>ea0258326-8k_modular.htm
<DESCRIPTION>CURRENT REPORT
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:us-roles="http://fasb.org/us-roles/2025" xmlns:country="http://xbrl.sec.gov/country/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:MODD="http://modularmedical.com/20250922">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html"/>
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02E_US%2DGAAP%2D2025 -->
<!-- Field: Set; Name: xdx; ID: xdx_03F_MODD_modularmedical.com_20250922 -->
<!-- Field: Set; Name: xdx; ID: xdx_04E_20250922_20250922 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_05D_edei%2D%2DEntityCentralIndexKey_0001074871 -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="AsOf2025-09-22" id="Fact000003" name="dei:AmendmentFlag">false</ix:nonNumeric>
  <ix:nonNumeric contextRef="AsOf2025-09-22" id="Fact000004" name="dei:EntityCentralIndexKey">0001074871</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="modd-20250922.xsd" xlink:type="simple"/>
  </ix:references>
 <ix:resources>
    <xbrli:context id="AsOf2025-09-22">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001074871</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2025-09-22</xbrli:startDate>
        <xbrli:endDate>2025-09-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_907_edei--DocumentType_c20250922__20250922_zbqTNSPsc0pc"><ix:nonNumeric contextRef="AsOf2025-09-22" id="Fact000009" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event Reported):
<span id="xdx_90E_edei--DocumentPeriodEndDate_c20250922__20250922_zwB9XvsadE6e"><ix:nonNumeric contextRef="AsOf2025-09-22" format="ixt:datemonthdayyearen" id="Fact000010" name="dei:DocumentPeriodEndDate">September 22, 2025</ix:nonNumeric></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_904_edei--EntityRegistrantName_c20250922__20250922_zh40N0coKcr"><ix:nonNumeric contextRef="AsOf2025-09-22" id="Fact000011" name="dei:EntityRegistrantName">MODULAR MEDICAL, INC.</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Exact Name of Registrant as Specified in Charter)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_907_edei--EntityFileNumber_c20250922__20250922_zX0FHZBk2Gcc"><ix:nonNumeric contextRef="AsOf2025-09-22" id="Fact000012" name="dei:EntityFileNumber">001-41277</ix:nonNumeric></span>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Commission File Number)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 49%"><span id="xdx_906_edei--EntityIncorporationStateCountryCode_c20250922__20250922_zQYN68K1O01k"><ix:nonNumeric contextRef="AsOf2025-09-22" format="ixt-sec:stateprovnameen" id="Fact000013" name="dei:EntityIncorporationStateCountryCode">Nevada</ix:nonNumeric></span></td>
    <td style="padding-bottom: 1.5pt; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 49%"><span id="xdx_908_edei--EntityTaxIdentificationNumber_c20250922__20250922_zFbIHjG63aVc"><ix:nonNumeric contextRef="AsOf2025-09-22" id="Fact000014" name="dei:EntityTaxIdentificationNumber">87-0620495</ix:nonNumeric></span></td></tr>
  <tr style="vertical-align: top">
    <td style="text-align: center">(State or Other Jurisdiction<br/>
    of Incorporation)</td>
    <td>&#160;</td>
    <td style="text-align: center">(I.R.S. Employer<br/>
    Identification Number)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_90B_edei--EntityAddressAddressLine1_c20250922__20250922_zdjpccOGYSg5"><ix:nonNumeric contextRef="AsOf2025-09-22" id="Fact000015" name="dei:EntityAddressAddressLine1">10740 Thornmint Road</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_906_edei--EntityAddressCityOrTown_c20250922__20250922_zfdMjrPDiI08"><ix:nonNumeric contextRef="AsOf2025-09-22" id="Fact000016" name="dei:EntityAddressCityOrTown">San Diego</ix:nonNumeric></span>, <span id="xdx_90F_edei--EntityAddressStateOrProvince_c20250922__20250922_zb48hsHqOYk2"><ix:nonNumeric contextRef="AsOf2025-09-22" format="ixt-sec:stateprovnameen" id="Fact000017" name="dei:EntityAddressStateOrProvince">California</ix:nonNumeric></span> <span id="xdx_90D_edei--EntityAddressPostalZipCode_c20250922__20250922_zdLQ0ZjAw7T5"><ix:nonNumeric contextRef="AsOf2025-09-22" id="Fact000018" name="dei:EntityAddressPostalZipCode">92127</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices, with
zip code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_905_edei--CityAreaCode_c20250922__20250922_zITHUBAVFd8b"><ix:nonNumeric contextRef="AsOf2025-09-22" id="Fact000019" name="dei:CityAreaCode">858</ix:nonNumeric></span>) <span id="xdx_902_edei--LocalPhoneNumber_c20250922__20250922_z052RYTyGHvc"><ix:nonNumeric contextRef="AsOf2025-09-22" id="Fact000020" name="dei:LocalPhoneNumber">800-3500</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_902_edei--WrittenCommunications_c20250922__20250922_zbXJcTnKwNp6"><ix:nonNumeric contextRef="AsOf2025-09-22" format="ixt:booleanfalse" id="Fact000021" name="dei:WrittenCommunications">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_900_edei--SolicitingMaterial_c20250922__20250922_zE0DDSWj3abl"><ix:nonNumeric contextRef="AsOf2025-09-22" format="ixt:booleanfalse" id="Fact000022" name="dei:SolicitingMaterial">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--PreCommencementTenderOffer_c20250922__20250922_zFPyy0NPJaeh"><ix:nonNumeric contextRef="AsOf2025-09-22" format="ixt:booleanfalse" id="Fact000023" name="dei:PreCommencementTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%">
  <tr style="vertical-align: top">
    <td style="width: 0.25in"><span style="font-family: Times New Roman, Times, Serif"><span id="xdx_903_edei--PreCommencementIssuerTenderOffer_c20250922__20250922_zA7aMn9aWLLg"><ix:nonNumeric contextRef="AsOf2025-09-22" format="ixt:booleanfalse" id="Fact000024" name="dei:PreCommencementIssuerTenderOffer">&#9744;</ix:nonNumeric></span></span></td>
    <td style="text-align: justify">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Securities registered pursuant to Section 12(b) of the Act:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%">Title of each class</td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: bottom; text-align: center; width: 32%">Trading Symbol(s)</td>
    <td style="vertical-align: top; width: 2%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; vertical-align: top; padding-left: 12.15pt; text-align: center; width: 32%">Name of each exchange
    on which registered</td></tr>
  <tr style="vertical-align: top; background-color: #CCEEFF">
    <td style="text-align: center"><span id="xdx_903_edei--Security12bTitle_c20250922__20250922_z0epCAIojqs6"><ix:nonNumeric contextRef="AsOf2025-09-22" id="Fact000025" name="dei:Security12bTitle">Common Stock</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center"><span id="xdx_901_edei--TradingSymbol_c20250922__20250922_zgT1JlZxxMRa"><ix:nonNumeric contextRef="AsOf2025-09-22" id="Fact000026" name="dei:TradingSymbol">MODD</ix:nonNumeric></span></td>
    <td>&#160;</td>
    <td style="text-align: center">The <span id="xdx_902_edei--SecurityExchangeName_c20250922__20250922_zf7EfWsWszqj"><ix:nonNumeric contextRef="AsOf2025-09-22" format="ixt-sec:exchnameen" id="Fact000027" name="dei:SecurityExchangeName">Nasdaq</ix:nonNumeric></span> Stock Market LLC</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR&#167;230.405) or Rule 12b-2 of the Securities
Exchange Act of 1934 (17 CFR &#167;240.12b-2).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Emerging growth company <span style="font-family: Times New Roman, Times, Serif"><span id="xdx_909_edei--EntityEmergingGrowthCompany_c20250922__20250922_zzhWtNLHFpp3"><ix:nonNumeric contextRef="AsOf2025-09-22" format="ixt:booleanfalse" id="Fact000028" name="dei:EntityEmergingGrowthCompany">&#9744;</ix:nonNumeric></span></span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Times New Roman, Times, Serif">&#9744;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 1.01 Entry into
a Material Definitive Agreement.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As previously disclosed,
in May 2023, Modular Medical, Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement with Newbridge Securities Corporation
(&#8220;Newbridge&#8221;) and issued, in connection with an underwritten offering, warrants to purchase 3,564,183 shares of the Company&#8217;s
common stock (the &#8220;2023 Warrants&#8221;) with the 2023 Warrants having an exercise price of $1.22 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">As previously disclosed,
in March 2025, the Company issued, in connection with a private placement, warrants to purchase 6,508,073 shares of the Company&#8217;s
common stock (the &#8220;2025 Warrants&#8221; and, together with the 2023 Warrants, the &#8220;Outstanding Warrants&#8221;) with the
2025 Warrants having an exercise price of $1.12 per share.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 22, 2025, the Company entered into inducement offer letter
agreements (the &#8220;2023 Inducement Letters&#8221;) with holders of the 2023 Warrants representing warrants to purchase 1,519,200 shares
of the Company&#8217;s common stock. Pursuant to the 2023 Inducement Letters, the holders agreed to exercise these 2023 Warrants at an
exercise price of $0.68 per share, an approximately ten percent (10%) discount to the $0.7611 Nasdaq Official Closing Price on September
19, 2025 (such reduced exercise price, the &#8220;New Exercise Price&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">On September 22, 2025, the Company entered into inducement offer letter
agreements (the &#8220;2025 Inducement Letters&#8221; and, together with the 2023 Inducement Letters, the &#8220;Warrant Letters&#8221;)
with holders of the 2025 Warrants representing warrants to purchase 3,975,428 shares of the Company&#8217;s common stock. Pursuant to
the 2025 Inducement Letters, the holders agreed to exercise these 2025 Warrants at the New Exercise Price. As a result of entering into
the Warrant Letters, the Company will receive gross proceeds of approximately $3.7 million, before deducting expenses related to the Company
entering into the Warrant Letters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">In consideration for the holders of the Outstanding Warrants agreeing
to enter into the Warrant Letters, the Company agreed to issue new warrants to purchase approximately 2,747,314 shares of the Company&#8217;s
common stock (the &#8220;New Warrants&#8221;) (fifty percent (50%) of the Outstanding Warrants exercised pursuant to the Warrant Letters)
with an exercise price of $0.84 per share (an approximately ten percent (10%) premium to the $0.7611 Nasdaq Official Closing Price on
September 19, 2025). The transaction is expected to close on or about September 25, 2025 (the &#8220;Closing Date&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The New Warrants will be issued with a Securities Act of 1933, as amended
(the &#8220;Securities Act&#8221;), restrictive legend and will be exercisable on the date of issuance and have a term of exercise of
5 years from the date of issuance. The Company will use commercially reasonable efforts to register the resale of the shares of the Company&#8217;s
common stock underlying the New Warrants (the &#8220;New Warrant Shares&#8221;). There is no established trading market for the New Warrants,
and the Company does not expect an active trading market to develop. The Company does not intend to apply to list the New Warrants on
any securities exchange or other trading market. Without a trading market, the liquidity of the New Warrants will be extremely limited.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">If, at the time a holder
exercises its New Warrants, a registration statement registering the resale of the New Warrant Shares by the holder under the Securities
Act is not then effective or available, then in lieu of making the cash payment otherwise contemplated to be made to the Company upon
such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole
or in part), the net number of shares of Common Stock determined according to a formula set forth in the New Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company expects
to enter into further Warrant Letters prior to the Closing Date and will release additional disclosure as to the final amounts of Outstanding
Warrants exercised and the number of New Warrants issued.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Newbridge acted as the servicing agent (solely for informational and
logistical purposes) with regard to the Warrant Letters and will receive a fixed fee of $400,000 and expense reimbursement of up to $50,000,
regardless of the amount of gross proceeds that the Company receives from the exercise of the Outstanding Warrants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"></p>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The shares of the Company&#8217;s common stock, par value $0.001 per
share (the &#8220;Common Stock&#8221;) issuable upon exercise of the 2023 Warrants have been registered pursuant to an existing registration
statement on Form S-3 (File No. 333-271413), declared effective by the Securities and Exchange Commission (the &#8220;SEC&#8221;) on August
19, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The resale of the shares
of Common Stock underlying the 2025 Warrants exercised have been registered pursuant to an existing registration statement on Form S-3
(File No. 333-286768), declared effective by the SEC on May 7, 2025.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The forms of the 2023 Inducement Letters, the 2025 Inducement Letters,
and New Warrants are attached hereto as Exhibits 10.1, 10.2, and 4.1, respectively. The description of the terms of the Warrant Letters
and the New Warrants is not intended to be complete and is qualified in its entirety by reference to such exhibits.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 3.02 Unregistered
Sales of Equity Securities.</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The Company issued
the New Warrants in reliance on the exemption provided by Section 3(a)(9) of the Securities Act as involving an exchange by the
Company exclusively with its security holders, Section 4(a)(2) of the Securities Act as a transaction not involving a public
offering and Rule 506 promulgated thereunder and in reliance on similar exemptions under applicable state laws with such reliance on
Rule 506 based in part upon a representation of each of the holders of the Outstanding Warrants who signed Warrant Letters that they
are an &#8220;accredited investor&#8221; as defined in Rule 501 promulgated pursuant to the Securities Act. Neither the issuance of
the New Warrants nor the New Warrant Shares have been registered under the Securities Act and such securities may not be offered or
sold in the United States absent registration or an exemption from registration under the Securities Act and any applicable state
securities laws. The description of the New Warrants under Item 1.01 of this Form 8-K is incorporated by reference herein.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">Neither this Current
Report on Form 8-K nor any exhibit attached hereto is an offer to sell or the solicitation of an offer to buy the Company&#8217;s securities.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><b>Item 9.01 Financial
Statements and Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><b>(d) Exhibits</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">The following exhibits
are filed with this report:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid; width: 9%"><b>Exhibit<br/>
    Number</b></td>
    <td style="padding-bottom: 1.5pt; text-align: center; width: 1%">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: center; width: 90%"><b>Exhibit Description</b></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td>4.1</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea025832601ex4-1_modular.htm">Form of Common Stock Purchase Warrant</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td>10.1</td>
    <td>&#160;</td>
    <td style="text-align: justify"><a href="ea025832601ex10-1_modular.htm">Form of 2023 Inducement Letter</a></td></tr>
  <tr style="vertical-align: top; background-color: rgb(204,238,255)">
    <td style="text-align: justify">10.2</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify"><a href="ea025832601ex10-2_modular.htm">Form of 2025 Inducement Letter</a></td></tr>
  <tr style="vertical-align: top; background-color: White">
    <td style="text-align: justify">104</td>
    <td style="text-align: justify">&#160;</td>
    <td style="text-align: justify">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Page; Sequence: 3; Value: 1 -->
    <div style="border-bottom: Black 1.5pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURE</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><b>MODULAR MEDICAL, INC.</b></td></tr>
  <tr style="vertical-align: top">
    <td style="width: 60%">&#160;</td>
    <td style="width: 3%">&#160;</td>
    <td style="width: 37%">&#160;</td></tr>
  <tr style="vertical-align: top">
    <td>Date: September 23, 2025</td>
    <td>By:&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><i>/s/ James E. Besser</i></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>James E. Besser</td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>Chief Executive Officer</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">3</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<!-- Field: Rule-Page --><div style="width: 100%"><div style="border-top: Black 1.5pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjdEKwjAMRb9g/xD6LDorE9yjQ4c4RcYQX4uLUtyakVbdPsm/tNsQQyAk955cISYipa2ukOGyzjMosG4q5RByvCGjuaJ3JLt9DH7meNfWsTJuWH9gQp5BzyynUvn74Hxpi2UM4Wom5UxGEEaxXMDpIIJeT8jcdInGaVWBMiWcmBrW6BR344dCtWSo7oakM7LVZGKYT8NR/oAM5xKO9FJv4oeFLEtEMBkqECnTs/GuTevQ9CRsKqx9nB3pfwdfzUpKXw== -->
</body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>ea025832601ex4-1_modular.htm
<DESCRIPTION>FORM OF COMMON STOCK PURCHASE WARRANT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: right"><B>Exhibit 4.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">NEITHER THIS SECURITY NOR THE SECURITIES
FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF
ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE &ldquo;SECURITIES ACT&rdquo;),
AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT
TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE
WITH APPLICABLE STATE SECURITIES LAWS. THIS SECURITY AND THE SECURITIES ISSUABLE UPON EXERCISE OF THIS SECURITY MAY BE PLEDGED IN CONNECTION
WITH A BONA FIDE MARGIN ACCOUNT OR OTHER LOAN SECURED BY SUCH SECURITIES.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">COMMON STOCK PURCHASE WARRANT
MODULAR MEDICAL, INC.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 33%">Warrant Shares: [&#9679;]</TD>
  <TD STYLE="width: 34%">&nbsp;</TD>
  <TD STYLE="text-align: right; width: 33%">Issue Date:
[&#9679;][&#9679;], 2025</TD></TR>
</TABLE>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">THIS COMMON STOCK
PURCHASE WARRANT (the &ldquo;<U>Warrant</U>&rdquo;) certifies that, for value received, [&#9679;] or its assigns (the &ldquo;<U>Holder</U>&rdquo;)
is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after
the date hereof (the &ldquo;<U>Initial Exercise Date</U>&rdquo;) and on or prior to 5:00 p.m. (New York City time) on [&#9679;] [&#9679;],
2030 (the &ldquo;<U>Termination Date</U>&rdquo;) but not thereafter, to subscribe for and purchase from Modular Medical, Inc., a Nevada
corporation (the &ldquo;<U>Company</U>&rdquo;), one share (as subject to adjustment hereunder, the &ldquo;<U>Warrant Shares</U>&rdquo;)
of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in
Section 2(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><U>Section 1</U>.
<U>Definitions</U>. In addition to the terms defined elsewhere in this Warrant, for all purposes of this Warrant, the following terms
have the meanings set forth in this Section 1:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; margin-top: 0pt; margin-bottom: 0pt">:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;<U>Affiliate</U>&rdquo;
means any Person that, directly or indirectly through one or more intermediaries, controls or is controlled by or is under common control
with a Person as such terms are used in and construed under Rule 405 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;<U>Business
Day</U>&rdquo; means any day except any Saturday, any Sunday, any day which is a federal legal holiday in the United States or any day
on which banking institutions in the State of New York are authorized or required by law or other governmental action to close.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;Commission&rdquo; means the Securities and Exchange
Commission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;<U>Common Stock</U>&rdquo; means the Company&rsquo;s
common stock, par value $0.001 per share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;<U>Common
Stock Equivalents</U>&rdquo; means any securities of the Company which would entitle the holder thereof to acquire at any time Common
Stock, including, without limitation, any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible
into or exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;<U>Exchange
Act</U>&rdquo; means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;<U>Person</U>&rdquo;
means an individual or corporation, partnership, trust, incorporated or unincorporated association, joint venture, limited liability company,
joint stock company, government (or an agency or subdivision thereof) or other entity of any kind.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;<U>Rule
144</U>&rdquo; means Rule 144 promulgated by the Commission pursuant to the Securities Act, as such Rule may be amended or interpreted
from time to time, or any similar rule or regulation hereafter adopted by the Commission having substantially the same purpose and effect
as such rule.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;<U>Securities
Act</U>&rdquo; means the Securities Act of 1933, as amended, and the rules and regulations promulgated thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;<U>Trading Day</U>&rdquo; means a day on which the
principal Trading Market is open for trading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;<U>Trading
Market</U>&rdquo; means the Nasdaq Global Market or any of the following markets or exchanges on which the Common Stock is then listed
or quoted for trading on the date in question: the Nasdaq Capital Market, the Nasdaq Global Market or the Nasdaq Global Select Market
(or any successors to any of the foregoing).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;<U>Transfer
Agent</U>&rdquo; means Colonial Stock Transfer Company, Inc., with offices located at 7840 S 700 E, Sandy, Utah 84070, and any successor
transfer agent of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>Section 2</U>. <U>Exercise</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">a) <U>Exercise
of Warrant</U>. Exercise of the purchase rights represented by this Warrant may be made, in whole or in part, at any time or times on
or after the Initial Exercise Date and on or before the Termination Date by delivery to the Company of a duly executed facsimile copy
or PDF copy submitted by e-mail (or e-mail attachment) of the Notice of Exercise in the form annexed hereto (the &ldquo;<U>Notice of Exercise</U>&rdquo;).
Within the earlier of (i) one (1) Trading Day and (ii) the number of Trading Days comprising the Standard Settlement Period (as defined
in Section 2(d)(i) herein) following the date of exercise as aforesaid, the Holder shall deliver the aggregate Exercise Price for the
Warrant Shares specified in the applicable Notice of Exercise by wire transfer or cashier&rsquo;s check drawn on a United States bank
unless the cashless exercise procedure specified in Section 2(c) below is specified in the applicable Notice of Exercise. No ink-original
Notice of Exercise shall be required, nor shall any medallion guarantee (or other type of guarantee or notarization) of any Notice of
Exercise be required. Notwithstanding anything herein to the contrary, the Holder shall not be required to physically surrender this Warrant
to the Company until the Holder has purchased all of the Warrant Shares available hereunder and the Warrant has been exercised in full,
in which case, the Holder shall surrender this Warrant to the Company for cancellation within three (3) Trading Days of the date on which
the final Notice of Exercise is delivered to the Company. Partial exercises of this Warrant resulting in purchases of a portion of the
total number of Warrant Shares available hereunder shall have the automatic effect of lowering the outstanding number of Warrant Shares
purchasable hereunder in an amount equal to the applicable number of Warrant Shares purchased. The Holder and the Company shall maintain
records showing the number of Warrant Shares purchased and the date of such purchases. The Company shall deliver any objection to any
Notice of Exercise within one (1) Trading Day of receipt of such notice. <B>The Holder and any assignee, by acceptance of this Warrant,
acknowledge and agree that, by reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder,
the number of Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">b) <U>Exercise
Price</U>. The exercise price per share of Common Stock under this Warrant shall be $0.84 subject to adjustment hereunder (the &ldquo;<U>Exercise
Price</U>&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">c) <U>Cashless
Exercise</U>. If at the time of exercise hereof there is no effective registration statement registering, or the prospectus contained
therein is not available for, the resale of the Warrant Shares by the Holder, then this Warrant may also be exercised, in whole or in
part, at such time by means of a &ldquo;cashless exercise&rdquo; in which the Holder shall be entitled to receive a number of Warrant
Shares equal to the quotient obtained by dividing [(A-B) (X)] by (A), where:</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>




<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(A) =</TD><TD STYLE="text-align: justify">as
applicable: (i) the VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise if such Notice of Exercise
is (1) both executed and delivered pursuant to Section 2(a) hereof on a day that is not a Trading Day or (2) both executed and delivered
pursuant to Section 2(a) hereof on a Trading Day prior to the opening of &ldquo;regular trading hours&rdquo; (as defined in Rule 600(b)
of Regulation NMS promulgated under the federal securities laws) on such Trading Day, (ii) at the option of the Holder, either (y) the
VWAP on the Trading Day immediately preceding the date of the applicable Notice of Exercise or (z) the Bid Price of the Common Stock
on the principal Trading Market as reported by Bloomberg L.P. (&ldquo;<U>Bloomberg</U>&rdquo;) as of the time of the Holder&rsquo;s execution
of the applicable Notice of Exercise if such Notice of Exercise is executed during &ldquo;regular trading hours&rdquo; on a Trading Day
and is delivered within two (2) hours thereafter (including until two (2) hours after the close of &ldquo;regular
trading hours&rdquo; on a Trading Day) pursuant to Section 2(a) hereof or (iii) the VWAP on the date of the applicable Notice of Exercise
if the date of such Notice of Exercise is a Trading Day and such Notice of Exercise is both executed and delivered pursuant to Section
2(a) hereof after the close of &ldquo;regular trading hours&rdquo; on such Trading Day;</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(B) = </TD><TD STYLE="text-align: justify">the Exercise Price of this Warrant, as adjusted hereunder;
and</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">(X) = </TD><TD STYLE="text-align: justify">the number of Warrant Shares that would be issuable upon exercise
of this Warrant in accordance with the terms of this Warrant if such exercise were by means of a cash exercise rather than a cashless
exercise.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If Warrant Shares
are issued in such a cashless exercise, the parties acknowledge and agree that in accordance with Section 3(a)(9) of the Securities Act,
the Warrant Shares shall take on the characteristics of the Warrants being exercised, and the holding period of the Warrant Shares being
issued may be tacked on to the holding period of this Warrant. The Company agrees not to take any position contrary to this Section 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;<U>Bid Price</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed or
quoted on a Trading Market, the bid price of the Common Stock for the time in question (or the nearest preceding date) on the Trading
Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from 9:30 a.m. (New York City
time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume weighted average price of the Common
Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the Common Stock is not then listed or quoted
for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The Pink Open Market (or a similar organization
or agency succeeding to its functions of reporting prices), the most recent bid price per share of the Common Stock so reported, or (d)
in all other cases, the fair market value of a share of Common Stock as determined by an independent appraiser selected in good faith
by the Holders of a majority in interest of the Warrant Shares available for purchase hereunder on such date and reasonably acceptable
to the Company, the fees and expenses of which shall be paid by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&ldquo;<U>VWAP</U>&rdquo;
means, for any date, the price determined by the first of the following clauses that applies: (a) if the Common Stock is then listed
or quoted on a Trading Market, the daily volume weighted average price of the Common Stock for such date (or the nearest preceding
date) on the Trading Market on which the Common Stock is then listed or quoted as reported by Bloomberg (based on a Trading Day from
9:30 a.m. (New York City time) to 4:02 p.m. (New York City time)), (b) if OTCQB or OTCQX is not a Trading Market, the volume
weighted average price of the Common Stock for such date (or the nearest preceding date) on OTCQB or OTCQX as applicable, (c) if the
Common Stock is not then listed or quoted for trading on OTCQB or OTCQX and if prices for the Common Stock are then reported on The
Pink Open Market (or a similar organization or agency succeeding to its functions of reporting prices), the most recent bid price
per share of the Common Stock so reported, or (d) in all other cases, the fair market value of a share of Common Stock as determined
by an independent appraiser selected in good faith by the Holders of a majority in interest of the Warrant Shares available for
purchase hereunder on such date and reasonably acceptable to the Company, the fees and expenses of which shall be paid by the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> d) <U>Mechanics of Exercise</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">i. <U>Delivery
of Warrant Shares Upon Exercise</U>. The Company shall cause the Warrant Shares purchased hereunder to be transmitted by the
Transfer Agent to the Holder by crediting the account of the Holder&rsquo;s or its designee&rsquo;s balance account with The
Depository Trust Company through its Deposit or Withdrawal at Custodian system (&ldquo;<U>DWAC</U>&rdquo;) if the Company is then a
participant in such system and either (A) there is an effective registration statement permitting the issuance of the Warrant Shares
to or resale of the Warrant Shares by the Holder or (B) the Warrant Shares are eligible for resale by the Holder without volume or
manner-of-sale limitations pursuant to Rule 144 (assuming cashless exercise of the Warrants), and otherwise by physical delivery of
a certificate, registered in the Company&rsquo;s share register in the name of the Holder or its designee, for the number of Warrant
Shares to which the Holder is entitled pursuant to such exercise to the address specified by the Holder in the Notice of Exercise by
the date that is the later of (i) the earlier of (a) two (2) Trading Days after the delivery to the Company of the Notice of
Exercise and (b) the number of Trading Days comprising the Standard Settlement Period after the delivery to the Company of the
Notice of Exercise, and (ii) one (1) Trading Day after delivery of the aggregate Exercise Price to the Company (provided the
foregoing clause (ii) shall not apply in the event of a cashless exercise) (such date, the &ldquo;<U>Warrant Share Delivery
Date</U>&rdquo;). Upon delivery of the Notice of Exercise, the Holder shall be deemed for all corporate purposes to have become the
holder of record of the Warrant Shares with respect to which this Warrant has been exercised, irrespective of the date of delivery
of the Warrant Shares, provided that payment of the aggregate Exercise Price (other than in the case of a cashless exercise) is
received within the earlier of (i) two (2) Trading Days and (ii) the number of Trading Days comprising the Standard Settlement
Period following delivery of the Notice of Exercise. The Company agrees to maintain a transfer agent that is a participant in the
FAST program so long as this Warrant remains outstanding and exercisable. As used herein, &ldquo;<U>Standard Settlement
Period</U>&rdquo; means the standard settlement period, expressed in a number of Trading Days, on the Company&rsquo;s primary
Trading Market with respect to the Common Stock as in effect on the date of delivery of the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">ii. <U>Delivery
of New Warrants Upon Exercise</U>. If this Warrant shall have been exercised in part, the Company shall, at the request of a Holder and
upon surrender of this Warrant certificate, at the time of delivery of the Warrant Shares, deliver to the Holder a new Warrant evidencing
the rights of the Holder to purchase the unpurchased Warrant Shares called for by this Warrant, which new Warrant shall in all other respects
be identical with this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">iii. <U>Rescission
Rights</U>. If the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares pursuant to Section 2(d)(i)
by the Warrant Share Delivery Date, then the Holder will have the right to rescind such exercise by providing the Company with written
notice of rescission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">iv. <U>Compensation
for Buy-In on Failure to Timely Deliver Warrant Shares Upon Exercise</U>. In addition to any other rights available to the Holder, if
the Company fails to cause the Transfer Agent to transmit to the Holder the Warrant Shares in accordance with the provisions of Section
2(d)(i) above pursuant to an exercise on or before the Warrant Share Delivery Date (other than any such failure that is solely due to
any action or inaction by the Holder with respect to such exercise), and if after such date the Holder is required by its broker to purchase
(in an open market transaction or otherwise) or the Holder&rsquo;s brokerage firm otherwise purchases, shares of Common Stock to deliver
in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &ldquo;<U>Buy-In</U>&rdquo;),
then the Company shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder&rsquo;s total purchase price (including
brokerage commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number
of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue times (2) the price
at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either reinstate the
portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which case such exercise shall
be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been issued had the Company timely
complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases Common Stock having a total purchase
price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common Stock with an aggregate sale price giving
rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding sentence the Company shall be required to pay
the Holder $1,000. The Holder shall provide the Company written notice indicating the amounts payable to the Holder in respect of the
Buy- In and, upon request of the Company, evidence of the amount of such loss. Nothing herein shall limit a Holder&rsquo;s right to pursue
any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or
injunctive relief with respect to the Company&rsquo;s failure to timely deliver shares of Common Stock upon exercise of the Warrant as
required pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">v. <U>No
Fractional Shares or Scrip</U>. No fractional shares or scrip representing fractional shares shall be issued upon the exercise of this
Warrant. As to any fraction of a share which the Holder would otherwise be entitled to purchase upon such exercise, the Company shall,
at its election, either pay a cash adjustment in respect of such final fraction in an amount equal to such fraction multiplied by the
Exercise Price or round down to the next whole share.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">vi. <U>Charges,
Taxes and Expenses</U>. Issuance of Warrant Shares shall be made without charge to the Holder for any issue or transfer tax or other incidental
expense in respect of the issuance of such Warrant Shares, all of which taxes and expenses shall be paid by the Company, and such Warrant
Shares shall be issued in the name of the Holder or in such name or names as may be directed by the Holder; <U>provided</U>, <U>however</U>,
that, in the event that Warrant Shares are to be issued in a name other than the name of the Holder, this Warrant when surrendered for
exercise shall be accompanied by the Assignment Form attached hereto duly executed by the Holder and the Company may require, as a condition
thereto, the payment of a sum sufficient to reimburse it for any transfer tax incidental thereto. The Company shall pay all Transfer Agent
fees required for same-day processing of any Notice of Exercise and all fees to the Depository Trust Company (or another established clearing
corporation performing similar functions) required for same-day electronic delivery of the Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">vii. <U>Closing
of Books</U>. The Company will not close its stockholder books or records in any manner which prevents the timely exercise of this Warrant,
pursuant to the terms hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">e) <U>Holder&rsquo;s
Exercise Limitations</U>. The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to
exercise any portion of this Warrant, pursuant to Section 2 or otherwise, to the extent that after giving effect to such issuance
after exercise as set forth on the applicable Notice of Exercise, the Holder (together with the Holder&rsquo;s Affiliates, and any
other Persons acting as a group together with the Holder or any of the Holder&rsquo;s Affiliates (such Persons,
&ldquo;<U>Attribution Parties</U>&rdquo;)), would beneficially own in excess of the Beneficial Ownership Limitation (as defined
below). For purposes of the foregoing sentence, the number of shares of Common Stock beneficially owned by the Holder and its
Affiliates and Attribution Parties shall include the number of shares of Common Stock issuable upon exercise of this Warrant with
respect to which such determination is being made, but shall exclude the number of shares of Common Stock which would be issuable
upon (i) exercise of the remaining, nonexercised portion of this Warrant beneficially owned by the Holder or any of its Affiliates
or Attribution Parties and (ii) exercise or conversion of the unexercised or nonconverted portion of any other securities of the
Company (including, without limitation, any other Common Stock Equivalents) subject to a limitation on conversion or exercise
analogous to the limitation contained herein beneficially owned by the Holder or any of its Affiliates or Attribution Parties.
Except as set forth in the preceding sentence, for purposes of this Section 2(e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder, it being acknowledged by the
Holder that the Company is not representing to the Holder that such calculation is in compliance with Section 13(d) of the Exchange
Act and the Holder is solely responsible for any schedules required to be filed in accordance therewith. To the extent that the
limitation contained in this Section 2(e) applies, the determination of whether this Warrant is exercisable (in relation to other
securities owned by the Holder together with any Affiliates and Attribution Parties) and of which portion of this Warrant is
exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall be deemed to be the
Holder&rsquo;s determination of whether this Warrant is exercisable (in relation to other securities owned by the Holder together
with any Affiliates and Attribution Parties) and of which portion of this Warrant is exercisable, in each case subject to the
Beneficial Ownership Limitation. To ensure compliance with this restriction, each Holder shall be deemed to represent to the Company
each time it delivers a Notice of Exercise that such Notice of Exercise has not violated the restrictions set forth in this
paragraph, and the Company shall have no obligation to verify or confirm the accuracy of such determination and shall have no
liability for exercises of this Warrant that are not in compliance with the Beneficial Ownership Limitation (other than to the
extent that information on the number of outstanding shares of Common Stock of the Company is provided by the Company and relied
upon by the Holder), provided that any exercise of this Warrant and issuance of Common Stock in excess of the applicable Beneficial
Ownership Limitation shall be null and void. In addition, a determination as to any group status as contemplated above shall be
determined in accordance with Section 13(d) of the Exchange Act and the rules and regulations promulgated thereunder and the Company
shall have no obligation to verify or confirm the accuracy of such determination and shall have no liability for purported exercises
of this Warrant that are not in compliance with the Beneficial Ownership Limitation. For purposes of this Section 2(e), in
determining the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock
as reflected in (A) the Company&rsquo;s most recent periodic or annual report filed with the Securities and Exchange Commission, as
the case may be, (B) a more recent public announcement by the Company or (C) a more recent written notice by the Company or the
Transfer Agent setting forth the number of shares of Common Stock outstanding. Upon the written or oral request of a Holder, the
Company shall within one Trading Day confirm orally and in writing to the Holder the number of shares of Common Stock then
outstanding. In any case, the number of outstanding shares of Common Stock shall be determined after giving effect to the conversion
or exercise of securities of the Company, including this Warrant, by the Holder or its Affiliates or Attribution Parties since the
date as of which such number of outstanding shares of Common Stock was reported. The &ldquo;<U>Beneficial Ownership
Limitation</U>&rdquo; shall initially be 4.99% of the number of shares of the Common Stock outstanding immediately after giving
effect to the issuance of shares of Common Stock issuable upon exercise of this Warrant. The Holder, upon notice to the Company, may
increase or decrease the Beneficial Ownership Limitation provisions of this Section 2(e), provided that the Beneficial Ownership
Limitation in no event exceeds 19.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the
issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this Section 2(e) shall
continue to apply. Any increase in the Beneficial Ownership Limitation will not be effective until the 61st day after such notice is
delivered to the Company. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict
conformity with the terms of this Section 2(e) to correct this paragraph (or any portion hereof) which may be defective or
inconsistent with the intended Beneficial Ownership Limitation herein contained or to make changes or supplements necessary or
desirable to properly give effect to such limitation. The limitations contained in this paragraph shall apply to a successor holder
of this Warrant. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the
Beneficial Ownership Limitation shall not be deemed to be beneficially owned by the Holder for any purpose including for purposes of
Section 13(d) of the Exchange Act or Rule 16a-1(a)(1) promulgated under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U>Section 3</U>. <U>Certain Adjustments</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">a) <U>Stock
Dividends and Splits</U>. If the Company, at any time while this Warrant is outstanding: (i) pays a stock dividend or otherwise makes
a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of
Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Company upon exercise of this
Warrant), (ii) subdivides outstanding shares of Common Stock into a larger number of shares, (iii) combines (including by way of reverse
stock split) outstanding shares of Common Stock into a smaller number of shares, or (iv) issues by reclassification of shares of the Common
Stock any shares of capital stock of the Company, then in each case the Exercise Price shall be multiplied by a fraction of which the
numerator shall be the number of shares of Common Stock (excluding treasury shares, if any) outstanding immediately before such event
and of which the denominator shall be the number of shares of Common Stock outstanding immediately after such event, and the number of
shares issuable upon exercise of this Warrant shall be proportionately adjusted such that the aggregate Exercise Price of this Warrant
shall remain unchanged. Any adjustment made pursuant to this Section 3(a) shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution and shall become effective immediately after the effective
date in the case of a subdivision, combination or re-classification.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">b) <U>Subsequent
Rights Offerings</U>. In addition to any adjustments pursuant to Section 3(a) above, if at any time the Company grants, issues or sells
any Common Stock Equivalents or rights to purchase stock, warrants, securities or other property pro rata to the record holders of any
class of shares of Common Stock (the &ldquo;<U>Purchase Rights</U>&rdquo;), then the Holder will be entitled to acquire, upon the terms
applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder had held the number
of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise hereof, including
without limitation, the Beneficial Ownership Limitation) immediately before the date on which a record is taken for the grant, issuance
or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the grant, issue or sale of such Purchase Rights (<U>provided</U>, <U>however</U>, that, to the extent that the Holder&rsquo;s
right to participate in any such Purchase Right would result in the Holder exceeding the Beneficial Ownership Limitation, then the Holder
shall not be entitled to participate in such Purchase Right to such extent (or beneficial ownership of such shares of Common Stock as
a result of such Purchase Right to such extent) and such Purchase Right to such extent shall be held in abeyance for the Holder until
such time, if ever, as its right thereto would not result in the Holder exceeding the Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">c) <U>Pro
Rata Distributions</U>. During such time as this Warrant is outstanding, if the Company shall declare or make any dividend or other
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or
otherwise (including, without limitation, any distribution of cash, stock or other securities, property or options by way of a
dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction) (a
&ldquo;<U>Distribution</U>&rdquo;), at any time after the issuance of this Warrant, then, in each such case, the Holder shall be
entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had
held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on
exercise hereof, including without limitation, the Beneficial Ownership Limitation) immediately before the date of which a record is
taken for such Distribution, or, if no such record is taken, the date as of which the record holders of shares of Common Stock are
to be determined for the participation in such Distribution (<U>provided</U>, <U>however</U>, that, to the extent that the
Holder&rsquo;s right to participate in any such Distribution would result in the Holder exceeding the Beneficial Ownership
Limitation, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any shares of Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in
abeyance for the benefit of the Holder until such time, if ever, as its right thereto would not result in the Holder exceeding the
Beneficial Ownership Limitation).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 6; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">d) <U>Fundamental
Transaction</U>. If, at any time while this Warrant is outstanding, (i) the Company, directly or indirectly, in one or more related
transactions effects any merger or consolidation of the Company with or into another Person, in which the Company is not the
surviving entity and in which the stockholders of the Company immediately prior to such merger or consolidation do not own, directly
or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation (excluding a
merger effected solely to change the Company&rsquo;s name), (ii) the Company, directly or indirectly, effects any sale, lease,
license, assignment, transfer, conveyance or other disposition of all or substantially all of its assets in one or a series of
related transactions, (iii) any, direct or indirect, purchase offer, tender offer or exchange offer (whether by the Company or
another Person) is completed pursuant to which holders of Common Stock are permitted to sell, tender or exchange their shares for
other securities, cash or property and has been accepted by the holders of 50% or more of the outstanding Common Stock, (iv) the
Company, directly or indirectly, in one or more related transactions effects any reclassification, reorganization or
recapitalization of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted
into or exchanged for other securities, cash or property, or (v) the Company, directly or indirectly, in one or more related
transactions consummates a stock or share purchase agreement or other business combination (including, without limitation, a
reorganization, recapitalization, spin-off, merger or scheme of arrangement) with another Person or group of Persons whereby such
other Person or group acquires more than 50% of the outstanding shares of Common Stock (not including any shares of Common Stock
held by the other Person or other Persons making or party to, or associated or affiliated with the other Persons making or party to,
such stock or share purchase agreement or other business combination) (each a &ldquo;<U>Fundamental Transaction</U>&rdquo;), then,
upon any subsequent exercise of this Warrant, the Holder shall have the right to receive, for each Warrant Share that would have
been issuable upon such exercise immediately prior to the occurrence of such Fundamental Transaction, at the option of the Holder
(without regard to any limitation in <U>Section 2(e)</U> on the exercise of this Warrant), the number of shares of Common Stock of
the successor or acquiring corporation or of the Company, if it is the surviving corporation, and any additional consideration (the
&ldquo;<U>Alternate Consideration</U>&rdquo;) receivable as a result of such Fundamental Transaction by a holder of the number of
shares of Common Stock for which this Warrant is exercisable immediately prior to such Fundamental Transaction (without regard to
any limitation in <U>Section 2(e)</U> on the exercise of this Warrant). For purposes of any such exercise, the determination of the
Exercise Price shall be appropriately adjusted to apply to such Alternate Consideration based on the amount of Alternate
Consideration issuable in respect of one share of Common Stock in such Fundamental Transaction, and the Company shall apportion the
Exercise Price among the Alternate Consideration in a reasonable manner reflecting the relative value of any different components of
the Alternate Consideration. If holders of Common Stock are given any choice as to the securities, cash or property to be received
in a Fundamental Transaction, then the Holder shall be given the same choice as to the Alternate Consideration it receives upon any
exercise of this Warrant following such Fundamental Transaction. Notwithstanding anything to the contrary, in the event of a
Fundamental Transaction, other than in clause (i) above in connection with a merger or consolidation of the Company with any
Subsidiary or Affiliate whereby the stockholders of the Company do not own at least (x) 50.0% of the outstanding shares of Common
Stock and (y) 50.0% of the voting power of the surviving entity immediately after such merger or consolidation, the Company or any
Successor Entity (as defined below) shall, at the Holder&rsquo;s option, exercisable at any time concurrently with, or within 30
days after, the consummation of the Fundamental Transaction (or, if later, the date of the public announcement of the applicable
Fundamental Transaction), purchase this Warrant from the Holder by paying to the Holder an amount of cash equal to the Black Scholes
Value (as defined below) of the remaining unexercised portion of this Warrant on the date of the consummation of such Fundamental
Transaction; provided, however, that if the Fundamental Transaction is not within the Company&rsquo;s control, including not
approved by the Company&rsquo;s Board of Directors, Holder shall only be entitled to receive from the Company or any Successor
Entity the same type or form of consideration (and in the same proportion), at the Black Scholes Value of the unexercised portion of
this Warrant, that is being offered and paid to the holders of Common Stock of the Company in connection with the Fundamental
Transaction, whether that consideration be in the form of cash, stock or any combination thereof, or whether the holders of Common
Stock are given the choice to receive from among alternative forms of consideration in connection with the Fundamental Transaction;
provided, further, that if holders of Common Stock of the Company are not offered or paid any consideration in such Fundamental
Transaction, such holders of Common Stock will be deemed to have received common stock of the Successor Entity (which Entity may be
the Company following such Fundamental Transaction) in such Fundamental Transaction. &ldquo;Black Scholes Value&rdquo; means the
value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the &ldquo;OV&rdquo; function on Bloomberg
determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting (i) a
risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the remaining term of this Warrant as of such
date of request, (ii) an expected volatility equal to the remaining term of this Warrant obtained from the HVT function on Bloomberg
as of the Trading Day immediately prior to the public announcement of the applicable Fundamental Transaction or, if the Fundamental
Transaction is not publicly announced, the date the Fundamental Transaction is consummated, (iii) the underlying price per share
used in such calculation shall be the greater of (A) the sum of the price per share being offered in cash, if any, plus the per
share value of any non-cash consideration, if any, being offered in such Fundamental Transaction and (B) the greater of (x) the last
VWAP of the Common Stock immediately prior to the public announcement of such Fundamental Transaction and (y) the last VWAP of the
Common Stock immediately prior to the consummation of such Fundamental Transaction, (iv) a zero cost of borrow and (v) a 360 day
annualization factor. The payment of the Black Scholes Value will be made by wire transfer of immediately available funds (or such
other consideration) within the later of (i) five Business Days of the Holder&rsquo;s election and (ii) the date of consummation of
the Fundamental Transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 7; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company shall
cause any successor entity in a Fundamental Transaction in which the Company is not the survivor (the &ldquo;<U>Successor Entity</U>&rdquo;)
to assume in writing all of the obligations of the Company under this Warrant prior to such Fundamental Transaction and shall, at the
option of the Holder, deliver to the Holder in exchange for this Warrant a security of the Successor Entity evidenced by a written instrument
substantially similar in form and substance to this Warrant which is exercisable for a corresponding number of shares of capital stock
of such Successor Entity (or its parent entity) equivalent to the shares of Common Stock acquirable and receivable upon exercise of this
Warrant (without regard to any limitations on the exercise of this Warrant) prior to such Fundamental Transaction, and with an exercise
price which applies the Exercise Price hereunder to such shares of capital stock (but taking into account the relative value of the shares
of Common Stock pursuant to such Fundamental Transaction and the value of such shares of capital stock, such number of shares of capital
stock and such exercise price being for the purpose of protecting the economic value of this Warrant immediately prior to the consummation
of such Fundamental Transaction), and which is reasonably satisfactory in form and substance to the Holder. Upon the occurrence of any
such Fundamental Transaction, the Successor Entity shall succeed to, and be substituted for (so that from and after the date of such Fundamental
Transaction, the provisions of this Warrant referring to the &ldquo;Company&rdquo; shall refer instead to the Successor Entity), and may
exercise every right and power of the Company and shall assume all of the obligations of the Company under this Warrant with the same
effect as if such Successor Entity had been named as the Company herein. For clarity, the provisions of this <U>Section 3(d)</U> shall
only apply if and to the extent the Fundamental Transaction occurs while this Warrant is outstanding and exercisable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">e) <U>Calculations</U>.
All calculations under this Section 3 shall be made to the nearest cent or the nearest 1/100th of a share, as the case may be. For purposes
of this Section 3, the number of shares of Common Stock deemed to be issued and outstanding as of a given date shall be the sum of the
number of shares of Common Stock (excluding treasury shares, if any) issued and outstanding. Notwithstanding the foregoing, in no event
may the Exercise Price be adjusted below the par value of the Common Stock then in effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> f) <U>Notice to Holder</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">i. <U>Adjustment
to Exercise Price</U>. Whenever the Exercise Price is adjusted pursuant to any provision of this Section 3, the Company shall promptly
deliver to the Holder by facsimile or email a notice setting forth the Exercise Price after such adjustment and any resulting adjustment
to the number of Warrant Shares and setting forth a brief statement of the facts requiring such adjustment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 8; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">ii. <U>Notice
to Allow Exercise by Holder</U>. If (A) the Company shall declare a dividend (or any other distribution in whatever form) on the
Common Stock, (B) the Company shall declare a special nonrecurring cash dividend on or a redemption of the Common Stock, (C) the
Company shall authorize the granting to all holders of the Common Stock rights or warrants to subscribe for or purchase any shares
of capital stock of any class or of any rights, (D) the approval of any stockholders of the Company shall be required in connection
with any reclassification of the Common Stock, any consolidation or merger to which the Company is a party, any sale or transfer of
all or substantially all of its assets, or any compulsory share exchange whereby the Common Stock is converted into other
securities, cash or property, or (E) the Company shall authorize the voluntary or involuntary dissolution, liquidation or winding up
of the affairs of the Company, then, in each case, the Company shall cause to be delivered by facsimile or email to the Holder at
its last facsimile number or email address as it shall appear upon the Warrant Register of the Company, at least 10 calendar days
prior to the applicable record or effective date hereinafter specified, a notice (unless such information is filed with the
Securities and Exchange Commission, in which case a notice shall not be required) stating (x) the date on which a record is to be
taken for the purpose of such dividend, distribution, redemption, rights or warrants, or if a record is not to be taken, the date as
of which the holders of the Common Stock of record to be entitled to such dividend, distributions, redemption, rights or warrants
are to be determined or (y) the date on which such reclassification, consolidation, merger, sale, transfer or share exchange is
expected to become effective or close, and the date as of which it is expected that holders of the Common Stock of record shall be
entitled to exchange their shares of the Common Stock for securities, cash or other property deliverable upon such reclassification,
consolidation, merger, sale, transfer or share exchange; provided that the failure to deliver such notice or any defect therein or
in the delivery thereof shall not affect the validity of the corporate action required to be specified in such notice. The Holder
shall remain entitled to exercise this Warrant during the period commencing on the date of such notice to the effective date of the
event triggering such notice except as may otherwise be expressly set forth herein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">iii. <U>Voluntary
Adjustment By Company</U>. Subject to the rules and regulations of the Trading Market, the Company may at any time during the term of
this Warrant reduce the then current Exercise Price to any amount and for any period of time deemed appropriate by the Board of Directors
of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><U>Section 4</U>. <U>Transfer of Warrant</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">a) <U>Transferability</U>.
Subject to compliance with any applicable securities laws and the conditions set forth in Section 4(d) hereof and to the provisions of
Section 4.1 of the Purchase Agreement, this Warrant and all rights hereunder (including, without limitation, any registration rights)
are transferable, in whole or in part, upon surrender of this Warrant at the principal office of the Company or its designated agent,
together with a written assignment of this Warrant substantially in the form attached hereto duly executed by the Holder or its agent
or attorney and funds sufficient to pay any transfer taxes payable upon the making of such transfer. Upon such surrender and, if required,
such payment, the Company shall execute and deliver a new Warrant or Warrants in the name of the assignee or assignees, as applicable,
and in the denomination or denominations specified in such instrument of assignment, and shall issue to the assignor a new Warrant evidencing
the portion of this Warrant not so assigned, and this Warrant shall promptly be cancelled. Notwithstanding anything herein to the contrary,
the Holder shall not be required to physically surrender this Warrant to the Company unless the Holder has assigned this Warrant in full,
in which case, the Holder shall surrender this Warrant to the Company within three (3) Trading Days of the date on which the Holder delivers
an assignment form to the Company assigning this Warrant in full. The Warrant, if properly assigned in accordance herewith, may be exercised
by a new holder for the purchase of Warrant Shares without having a new Warrant issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">b) <U>New
Warrants</U>. This Warrant may be divided or combined with other Warrants upon presentation hereof at the aforesaid office of the Company,
together with a written notice specifying the names and denominations in which new Warrants are to be issued, signed by the Holder or
its agent or attorney. Subject to compliance with Section 4(a), as to any transfer which may be involved in such division or combination,
the Company shall execute and deliver a new Warrant or Warrants in exchange for the Warrant or Warrants to be divided or combined in accordance
with such notice. All Warrants issued on transfers or exchanges shall be dated the original Issue Date and shall be identical with this
Warrant except as to the number of Warrant Shares issuable pursuant thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">c) <U>Warrant
Register</U>. The Company shall register this Warrant, upon records to be maintained by the Company for that purpose (the &ldquo;<U>Warrant
Register</U>&rdquo;), in the name of the record Holder hereof from time to time. The Company may deem and treat the registered Holder
of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any distribution to the Holder, and for all other
purposes, absent actual notice to the contrary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 9; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">d) <U>Transfer
Restrictions</U>. If, at the time of the surrender of this Warrant in connection with any transfer of this Warrant, the transfer of this
Warrant shall not be either (i) registered pursuant to an effective registration statement under the Securities Act and under applicable
state securities or blue sky laws or (ii) eligible for resale without volume or manner-of-sale restrictions or current public information
requirements pursuant to Rule 144, the Company may require, as a condition of allowing such transfer, that the Holder or transferee of
this Warrant, as the case may be, comply with the provisions of Section 5.7 of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">e) <U>Representation
by the Holder</U>. The Holder, by the acceptance hereof, represents and warrants that it is acquiring this Warrant and, upon any exercise
hereof, will acquire the Warrant Shares issuable upon such exercise, for its own account and not with a view to or for distributing or
reselling such Warrant Shares or any part thereof in violation of the Securities Act or any applicable state securities law, except pursuant
to sales registered or exempted under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><U>Section 5</U>. <U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">a) <U>No
Rights as Stockholder Until Exercise; No Settlement in Cash</U>. This Warrant does not entitle the Holder to any voting rights, dividends
or other rights as a stockholder of the Company prior to the exercise hereof as set forth in Section 2(d)(i), except as expressly set
forth in Section 3. Without limiting any rights of a Holder to receive Warrant Shares on a &ldquo;cashless exercise&rdquo; pursuant to
Section 2(c) or to receive cash payments pursuant to Section 2(d)(i) and Section 2(d)(iv) herein, in no event shall the Company be required
to net cash settle an exercise of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">b) <U>Loss,
Theft, Destruction or Mutilation of Warrant</U>. The Company covenants that upon receipt by the Company of evidence reasonably satisfactory
to it of the loss, theft, destruction or mutilation of this Warrant or any stock certificate relating to the Warrant Shares, and in case
of loss, theft or destruction, of indemnity or security reasonably satisfactory to it (which, in the case of the Warrant, shall not include
the posting of any bond), and upon surrender and cancellation of such Warrant or stock certificate, if mutilated, the Company will make
and deliver a new Warrant or stock certificate of like tenor and dated as of such cancellation, in lieu of such Warrant or stock certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">c) <U>Saturdays,
Sundays, Holidays, etc</U>. If the last or appointed day for the taking of any action or the expiration of any right required or granted
herein shall not be a Trading Day, then such action may be taken or such right may be exercised on the next succeeding Trading Day.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> d) <U>Authorized Shares</U>.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The Company covenants
that, during the period the Warrant is outstanding, it will reserve from its authorized and unissued Common Stock a sufficient number
of shares to provide for the issuance of the Warrant Shares upon the exercise of any purchase rights under this Warrant. The Company further
covenants that its issuance of this Warrant shall constitute full authority to its officers who are charged with the duty of issuing the
necessary Warrant Shares upon the exercise of the purchase rights under this Warrant. The Company will take all such reasonable action
as may be necessary to assure that such Warrant Shares may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of the Trading Market upon which the Common Stock may be listed. The Company covenants that all Warrant Shares
which may be issued upon the exercise of the purchase rights represented by this Warrant will, upon exercise of the purchase rights represented
by this Warrant and payment for such Warrant Shares in accordance herewith, be duly authorized, validly issued, fully paid and nonassessable
and free from all taxes, liens and charges created by the Company in respect of the issue thereof (other than taxes in respect of any
transfer occurring contemporaneously with such issue).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Except
and to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation,
amending its certificate of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without
limiting the generality of the foregoing, the Company will (i) not increase the par value of any Warrant Shares above the amount
payable therefor upon such exercise immediately prior to such increase in par value, (ii) take all such action as may be necessary
or appropriate in order that the Company may validly and legally issue fully paid and nonassessable Warrant Shares upon the exercise
of this Warrant and (iii) use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any
public regulatory body having jurisdiction thereof, as may be, necessary to enable the Company to perform its obligations under this
Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Page; Sequence: 10; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Before taking any
action which would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price,
the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any public regulatory
body or bodies having jurisdiction thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">e) <U>Jurisdiction</U>.
All questions concerning the construction, validity, enforcement and interpretation of this Warrant shall be determined in accordance
with the provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">f) <U>Restrictions</U>.
The Holder acknowledges that the Warrant Shares acquired upon the exercise of this Warrant, if not registered, and the Holder does not
utilize cashless exercise, will have restrictions upon resale imposed by state and federal securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">g) <U>Nonwaiver
and Expenses</U>. No course of dealing or any delay or failure to exercise any right hereunder on the part of Holder shall operate as
a waiver of such right or otherwise prejudice the Holder&rsquo;s rights, powers or remedies. Without limiting any other provision of this
Warrant or the Purchase Agreement, if the Company willfully and knowingly fails to comply with any provision of this Warrant, which results
in any material damages to the Holder, the Company shall pay to the Holder such amounts as shall be sufficient to cover any costs and
expenses including, but not limited to, reasonable attorneys&rsquo; fees, including those of appellate proceedings, incurred by the Holder
in collecting any amounts due pursuant hereto or in otherwise enforcing any of its rights, powers or remedies hereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">h) <U>Notices</U>.
Any notice, request or other document required or permitted to be given or delivered to the Holder by the Company shall be delivered in
accordance with the notice provisions of the Purchase Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">i) <U>Limitation
of Liability</U>. No provision hereof, in the absence of any affirmative action by the Holder to exercise this Warrant to purchase Warrant
Shares, and no enumeration herein of the rights or privileges of the Holder, shall give rise to any liability of the Holder for the purchase
price of any Common Stock or as a stockholder of the Company, whether such liability is asserted by the Company or by creditors of the
Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">j) <U>Remedies</U>.
The Holder, in addition to being entitled to exercise all rights granted by law, including recovery of damages, will be entitled to specific
performance of its rights under this Warrant. The Company agrees that monetary damages would not be adequate compensation for any loss
incurred by reason of a breach by it of the provisions of this Warrant and hereby agrees to waive and not to assert the defense in any
action for specific performance that a remedy at law would be adequate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">k) <U>Successors
and Assigns</U>. Subject to applicable securities laws, this Warrant and the rights and obligations evidenced hereby shall inure to the
benefit of and be binding upon the successors and permitted assigns of the Company and the successors and permitted assigns of Holder.
The provisions of this Warrant are intended to be for the benefit of any Holder from time to time of this Warrant and shall be enforceable
by the Holder or holder of Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">l) <U>Amendment</U>.
This Warrant may be modified or amended or the provisions hereof waived with the written consent of the Company and the Holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">m) <U>Severability</U>.
Wherever possible, each provision of this Warrant shall be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Warrant shall be prohibited by or invalid under applicable law, such provision shall be ineffective to the
extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">n) <U>Headings</U>.
The headings used in this Warrant are for the convenience of reference only and shall not, for any purpose, be deemed a part of this Warrant.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">********************</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>(Signature Page Follows)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 11; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">IN WITNESS WHEREOF, the Company has
caused this Common Stock Purchase Warrant to be executed by its officer thereunto duly authorized as of the date first above indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"><B>MODULAR MEDICAL, INC.</B></TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 35%">&nbsp;</TD>
  <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>By: </TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Name: </TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Title: </TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>[Signature Page to Common
Stock Warrant]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><I>&nbsp;</I></P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">NOTICE OF EXERCISE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0in"></TD><TD STYLE="width: 0.5in; text-align: left">TO:</TD><TD STYLE="text-align: justify">MODULAR MEDICAL, INC.</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(1)&nbsp;&nbsp;&nbsp;The
undersigned hereby elects to purchase ______________Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if exercised
in full), and tenders herewith payment of the exercise price in full, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> (2)&nbsp;&nbsp;&nbsp;Payment shall take the form of (check applicable box):</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> <FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;in lawful money of the United States; or</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in; text-indent: 0in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(3)&nbsp;&nbsp;&nbsp;Please issue said Warrant Shares in the
name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The Warrant Shares shall be delivered to the following DWAC Account
Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(4)&nbsp;&nbsp;&nbsp;<U>Accredited
Investor</U>. The undersigned is an &ldquo;accredited investor&rdquo; as defined in Regulation D promulgated under the Securities Act
of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Name of Investing Entity :
_________________________________________________________________________________________________</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Signature of Authorized
Signatory of Investing Entity </I> : ___________________________________________________________________________</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Name of Authorized Signatory
: _____________________________________________________________________________________________</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><U></U> Title
of Authorized Signatory : ______________________________________________________________________________________________</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Date
: __________________________________________________________________________________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">ASSIGNMENT FORM</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>(To assign the foregoing Warrant, execute
this form and supply required information. Do not use this form to purchase shares.)</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">FOR VALUE RECEIVED, the foregoing Warrant
and all rights evidenced thereby are hereby assigned to</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 25%">Name:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 35%">&nbsp;</TD>
  <TD STYLE="width: 40%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>(Please Print)</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Address:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>(Please Print)</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Phone Number:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Email Address:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Dated:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Holder&rsquo;s Signature:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Holder&rsquo;s Address:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>3
<FILENAME>ea025832601ex10-1_modular.htm
<DESCRIPTION>FORM OF 2023 INDUCEMENT LETTER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>Exhibit 10.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1pt"><B><I>Strictly Confidential</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">September 15, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Modular Medical, Inc.<BR>
 10740 Thornmint Road<BR>
 San Diego,
CA 92127</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">Re:</TD><TD STYLE="text-align: justify">Proposed Adjustment of Warrant Exercise Price of 2023 Warrant</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Dear Sir or Madam:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Reference
is hereby made to the Common Stock Purchase Warrant acquired by the undersigned Holder on May 18, 2023 (the &ldquo;2023 Warrant&rdquo;;
terms used but not defined herein have the meanings assigned to them in the 2023 Warrant and that certain Warrant Agency Agreement, by
and between Modular Medical, Inc. (the &ldquo;Company&rdquo;) and Colonial Stock Transfer Company, Inc., dated as of May 18, 2023) in
the Company&rsquo;s registered underwritten offering under the Underwriting Agreement between the Company and Newbridge Securities Corporation
(&ldquo;NSC&rdquo;). The 2023 Warrant is exercisable for ____________shares of Common Stock at an Exercise Price of $1.22 per share. All capitalized
terms not herein defined shall have the meaning ascribed to them in the 2023 Warrant, including all attachments, schedules and exhibits
thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Pursuant
to Section 3(g) of the Warrant Certificate, the Exercise Price may be reduced to any amount deemed appropriate by the board of
directors of the Company. The Company, by countersigning this letter where indicated below, agrees to adjust the Exercise Price,
such that the price paid by the Holder to exercise the 2023 Warrant shall be the Adjusted Exercise Price Per Share set forth on the
Notice of Exercise (attached as <U>Exhibit A</U>), which shall be the lower of (a) $0.70 per share of Common Stock or (b) a 10.0%
discount to the Nasdaq Official Closing Price (&ldquo;NOCP&rdquo;) on the date of such Notice of Exercise. In connection therewith,
the Holder is (i) submitting a Notice of Exercise, (ii) submitting a Warrant Certificate Request Notice (attached as <U>Exhibit
B</U>) and designating NSC to receive the physical certificate and submit it to the Company to be exercised, and (iii) paying the
aggregate exercise price listed on the Notice of Exercise to exercise the number of shares of Common Stock of the 2023 Warrant
listed on the Notice of Exercise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The
registration statement registering the resale of the shares underlying the 2023 Warrant is currently effective and, upon exercise of
the 2023 Warrant, will, to the Company&rsquo;s knowledge, be effective for the resale of the shares underlying the 2023 Warrant. In
consideration for the undersigned Holder exercising the 2023 Warrant, the Company hereby offers to issue to the undersigned Holder
or its designee a new unregistered common stock purchase warrant (&ldquo;New Warrants&rdquo;) pursuant to Section 4(a)(2) of the
Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), to purchase up to a number of shares of Common Stock (the
&ldquo;New Warrant Shares&rdquo;) equal to 50% of the number of Warrant Shares issued pursuant to the exercise of the 2023 Warrant
hereunder, which New Warrants shall be substantially in the form as set forth in Exhibit C hereto with such New Warrants having a
Securities Act restrictive legend , will be exercisable on the date of issuance and have a term of exercise of 5 years from the date
of issuance with an exercise price equal to the lower of (a) $1.00 per share or (b) a 10.0% premium to the NOCP on the date of the
Notice of Exercise, subject to adjustment as provided in the New Warrants. The Company will use commercially reasonable efforts to
register the resale of New Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"><B><I>Strictly Confidential</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The undersigned
Holder hereby represents and warrants that at the time the undersigned Holder was offered the New Warrants, it was, and as of the date
hereof it is, an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(4), (a)(5), (a)(6), (a)(7), (a)(8),
(a)(9), (a)(12) or (a)(13) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The undersigned
Holder acknowledges that NSC, acting as the Servicing Agent, shall receive a fixed fee of $400,000 and expense reimbursement of up to
$50,000, regardless of the amount of proceeds from the exercise of the 2023 Warrant or the New Warrants, and as the Servicing Agent, NSC
is acting solely for informational and logistical purposes only. The undersigned Holder understands that NSC is not making any investment
recommendation or offering any investment advice, and no communication from NSC should be construed as such.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.5in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">If
you have any questions regarding the logistics of exercising the 2023 Warrant, please contact NSC at Syndicate@newbridgesecurities.com.
If you have any other questions, please contact the Company at Warrantadjustment@modular-medical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The undersigned Holder and
the Company understand that this matter should be treated as confidential until such time as a press release is issued or a Current Report
on Form 8-K is filed regarding this matter.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sincerely,</FONT></TD>
  <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Investing Entity:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity:</I></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">Accepted and agreed:</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"> MODULAR MEDICAL, INC.</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 35%">&nbsp;</TD>
  <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Name:</TD>
  <TD> James E. Besser</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Title:</TD>
  <TD>Chief Executive Officer</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT A</U>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>NOTICE OF EXERCISE</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">TO: Modular Medical, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(1)&nbsp;&nbsp;&nbsp;The
undersigned hereby elects to purchase ___________Warrant Shares of the Company pursuant to the terms of the attached Warrant (only if
exercised in full) at an Adjusted Exercise Price of $____________, and tenders herewith payment of the aggregate exercise price in full
equal to $______________, together with all applicable transfer taxes, if any.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"> (2)&nbsp;&nbsp;&nbsp;Payment shall take the form of (check applicable box):</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; margin-top: 0pt; margin-bottom: 0pt">&#9746;&nbsp;&nbsp;&nbsp;in lawful money of the
United States; or</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin-left: 1.25in; margin-top: 0pt; margin-bottom: 0pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&#9744;&nbsp;&nbsp;&nbsp;</FONT>if
permitted the cancellation of such number of Warrant Shares as is necessary, in accordance with the formula set forth in subsection 2(c),
to exercise this Warrant with respect to the maximum number of Warrant Shares purchasable pursuant to the cashless exercise procedure
set forth in subsection 2(c).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; text-indent: 0.75in; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">(3)&nbsp;&nbsp;&nbsp;Please issue said Warrant
Shares in the name of the undersigned or in such other name as is specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">The Warrant Shares shall be delivered to the following DWAC Account
Number:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 30%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD>
  <TD STYLE="width: 30%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 38%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Investing Entity:</FONT></TD>
  <TD STYLE="width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Signature of Authorized Signatory of Investing Entity:</I></FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name of Authorized Signatory:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title of Authorized Signatory:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:</FONT></TD>
  <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
  <TD STYLE="border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT B</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">WARRANT CERTIFICATE REQUEST NOTICE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">To: Colonial Stock Transfer Company,
Inc as Warrant Agent for Modular Medical, Inc. (the &ldquo;Company&rdquo;)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The undersigned Holder of Common
Stock Purchase Warrants (&ldquo;Warrants&rdquo;) in the form of Global Warrants issued by the Company hereby elects to receive a Definitive
Certificate evidencing the Warrants held by the Holder as specified below:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.6pt"></TD><TD STYLE="width: 25.55pt">1.</TD><TD>Name of Holder of Warrants in form of Global Warrants:</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                     <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>__________________________________________________________</TD></TR>
                                                                                                                                     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.6pt"></TD><TD STYLE="width: 25.6pt">2.</TD><TD>Name of Holder in Definitive Certificate (if different from name of Holder of Warrants in form of Global
Warrants):</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="padding-right: 36.1pt">&nbsp;</TD></TR>
                    <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="padding-right: 36.1pt">__________________________________________________________</TD></TR>
                    </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.6pt"></TD><TD STYLE="width: 25.55pt">3.</TD><TD>Number of Warrants in name of Holder in form of Global Warrants:</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                               <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>__________________________________________________________</TD></TR>
                                                                                                                                               </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.6pt"></TD><TD STYLE="width: 25.55pt">4.</TD><TD>Number of Warrants for which Definitive Certificate shall be issued:</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>&nbsp;</TD></TR>
                                                                                                                                                   <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD>__________________________________________________________</TD></TR>
                                                                                                                                                   </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.6pt"></TD><TD STYLE="width: 25.6pt">5.</TD><TD>Number of Warrants in name of Holder in form of Global Warrants after issuance of Definitive Certificate,
if any:</TD></TR><TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="padding-right: 21.05pt">&nbsp;</TD></TR>
                 <TR STYLE="vertical-align: top">
<TD>&nbsp;</TD><TD>&nbsp;</TD><TD STYLE="padding-right: 21.05pt">_________________</TD></TR>
                 </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 20.6pt"></TD><TD STYLE="width: 25.6pt">6.</TD><TD STYLE="text-align: justify">Definitive Certificates shall be issued in book entry without physical delivery and reflect the following
address for the Holder:</TD></TR>
                                 </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt">Black River Management Ltd.<BR>
 15 Cattano Avenue</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt">Morristown, NJ 07960</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-left: 1in; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>

<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">The undersigned hereby acknowledges
and agrees that, in connection with this Warrant Exchange and the issuance of the Definitive Certificate, the Holder is deemed to have
surrendered the number of Warrants in form of Global Warrants in the name of the Holder equal to the number of Warrants evidenced by the
Definitive Certificate.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">[SIGNATURE OF HOLDER]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify">Name of Investing Entity:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>Signature of Authorized Signatory of Investing Entity:</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><I>&nbsp;</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Name of Authorized Signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Title of Authorized Signatory:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="margin-top: 0pt; margin-bottom: 0pt">__________________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">Date: ______________________________________</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B><U>EXHIBIT C</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>Form of New Warrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>[See attached]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>6</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><B>&nbsp;</B></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>4
<FILENAME>ea025832601ex10-2_modular.htm
<DESCRIPTION>FORM OF 2025 INDUCEMENT LETTER
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>Exhibit 10.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>Strictly Confidential</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B><I>&nbsp;</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">September 15, 2025</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 339.8pt 0pt 0">Modular Medical, Inc. 10740 Thornmint Road San Diego, CA
92127</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 339.8pt 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.5in; text-align: left">Re:</TD><TD STYLE="text-align: justify">Proposed Adjustment of Warrant Exercise Price of 2025 Warrant</TD>
</TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Dear Sir or Madam:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify; text-indent: 36.05pt">Reference
is hereby made to the Common Stock Purchase Warrant acquired by the undersigned Holder on March 25, 2025 (the &ldquo;2025
Warrant&rdquo;) in the Company&rsquo;s private offering for which Newbridge Securities Corporation (&ldquo;NSC&rdquo;) served as
placement agent. The 2025 Warrant is exercisable for ______________ shares of Common Stock at an Exercise Price of $1.12 per share.
All capitalized terms not herein defined shall have the meaning ascribed to them in the 2025 Warrant, including all attachments,
schedules and exhibits thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify; text-indent: 0.5in">Pursuant to Section
3(f)(iii) of the 2025 Warrant, the Exercise Price may be reduced to any amount deemed appropriate by the board of directors of the Company.
The Company, by countersigning this letter where indicated below, agrees to adjust the Exercise Price, such that the price paid by the
Holder to exercise the 2025 Warrant shall be the Adjusted Exercise Price Per Share set forth on the signature page attached hereto, which
shall be the lower of (a) $0.70 per share of Common Stock or (b) a 10.0% discount to the Nasdaq Official Closing Price (&ldquo;NOCP&rdquo;)
on the date of the signature page hereto. By signing this letter below the undersigned Holder accepts the offer to exercise the 2025 Warrant
at the adjusted Exercise Price in exchange for the New Warrants, with such acceptance constituting the undersigned Holder&rsquo;s exercise
of the 2025 Warrant as set forth on the Holder&rsquo;s signature page attached hereto for an aggregate exercise price as set forth on
the Holder&rsquo;s signature page hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25pt 0pt 0; text-align: justify; text-indent: 0.5in">The registration
statement registering the resale of the shares underlying the 2025 Warrant is currently effective and, upon exercise of the 2025 Warrant,
will, to the Company&rsquo;s knowledge, be effective for the resale of the shares underlying the 2025 Warrant. In consideration for the
undersigned Holder exercising the 2025 Warrant, the Company hereby offers to issue to the undersigned Holder or its designee a new unregistered
common stock purchase warrant (&ldquo;New Warrants&rdquo;) pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the
&ldquo;Securities Act&rdquo;), to purchase up to a number of shares of Common Stock (the &ldquo;New Warrant Shares&rdquo;) equal to 50%
of the number of Warrant Shares issued pursuant to the exercise of the 2025 Warrant hereunder, which New Warrants shall be substantially
in the form as set forth in Exhibit A hereto with such New Warrants having a Securities Act restrictive legend , will be exercisable on
the date of issuance and have a term of exercise of 5 years from the date of issuance with an exercise price equal to the lower of (a)
$$1.00 per share or (b) a 10.0% premium to the NOCP on the date of signature page hereto, subject to adjustment as provided in the New
Warrants. The Company will use commercially reasonable efforts to register the resale of New Warrant Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25pt 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned
Holder hereby represents and warrants that at the time the undersigned Holder was offered the New Warrants, it was, and as of the date
hereof it is, an &ldquo;accredited investor&rdquo; as defined in Rule 501(a)(1), (a)(2), (a)(3), (a)(4), (a)(5), (a)(6), (a)(7), (a)(8),
(a)(9), (a)(12) or (a)(13) under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.2pt 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned
Holder acknowledges that NSC, acting as the Servicing Agent, shall receive a fixed fee of $400,000 and expense reimbursement of up to
$50,000, regardless of the amount of proceeds from the exercise of the 2025 Warrant or the New Warrants, and as the Servicing Agent, NSC
is acting solely for informational and logistical purposes only. The undersigned Holder understands that NSC is not making any investment
recommendation or offering any investment advice, and no communication from NSC should be construed as such.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.35pt 0pt 0; text-align: justify; text-indent: 36.05pt">The undersigned
Holder and the Company understand that the Company may not issue, upon the exercise of the 2025 Warrant together with all other warrants
exercised for a price adjusted by the Company along with the issuance of the New Warrants, an aggregate number of shares of Common Stock
in excess of 19.99% of the number of shares of Common Stock outstanding prior to such issuances (the &ldquo;Maximum Issuance Amount&rdquo;),
in accordance with Rule 5635(d) of the Nasdaq Stock Market. The Company may decline to accept exercise of the 2025 Warrant at the adjusted
Exercise Price, or may accept only partial exercise of the 2025 Warrant at the adjusted Exercise Price, in order not to exceed the Maximum
Issuance Amount.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25pt 0pt 0; text-align: justify; text-indent: 0.5in">If you have any
questions regarding the logistics of exercising the 2025 Warrant, please contact NSC at Syndicate@newbridgesecurities.com. If you have
any other questions, please contact the Company at Warrantadjustment@modular-medical.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25pt 0pt 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0.25pt 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>




<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: justify; text-indent: 36.05pt">The
undersigned Holder and the Company understand that this matter should be treated as confidential until such time as a press release is
issued or a Current Report on Form 8-K is filed regarding this matter.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: justify; text-indent: 36.05pt">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 38%">Sincerely,</TD>
  <TD STYLE="width: 2%">&nbsp;</TD>
  <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Name of Warrant Holder</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD> Warrant Share Amount:</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Adjusted Exercise Price Per Share</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD> Aggregate Exercise
Price</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Signature of Authorized Signatory of Warrant Holder</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Name of Authorized
Signatory:</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Title of Authorized Signatory:</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Date:</TD>
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0">The Warrant Shares shall be delivered to the following DWAC Account
Number:</P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; font: 10pt Times New Roman, Times, Serif; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 30%">&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid; width: 40%">&nbsp;</TD>
  <TD STYLE="width: 30%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>&nbsp;</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>
<P STYLE="margin: 0"></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%">
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">Accepted and agreed:</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD COLSPAN="2"> MODULAR MEDICAL, INC.</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD STYLE="width: 5%">&nbsp;</TD>
  <TD STYLE="width: 35%">&nbsp;</TD>
  <TD STYLE="width: 60%">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>By:</TD>
  <TD STYLE="border-bottom: Black 1.5pt solid">&nbsp;</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Name:</TD>
  <TD> James E. Besser</TD>
  <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top; text-align: left">
  <TD>Title:</TD>
  <TD>Chief Executive Officer</TD>
  <TD>&nbsp;</TD></TR>
</TABLE>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: justify"></P>


<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0pt 0.3pt 0pt 0; text-align: justify; text-indent: 36.05pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>




<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.05pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.05pt; text-align: center"></P>

<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><P STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.05pt; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.05pt; text-align: center"><B><U>EXHIBIT A</U></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.05pt 0pt 176pt; text-align: center"><B>Form of New Warrant</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.05pt 0pt 176pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.05pt 0pt 176pt; text-align: center"><B>[See attached]</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.05pt 0pt 176pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.05pt 0pt 176pt; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.05pt 0pt 176pt; text-align: center">4</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.05pt 0pt 176pt; text-align: center"><B></B></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 176.05pt 0pt 176pt; text-align: center"><B>&nbsp;</B> </P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>modd-20250922.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: /qRZo7xRiXhun8uNbXQsSaqGaaPtypR1yYkxs2t1HWnqLy8saEluFik0upuGgfQM -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:srt-types="http://fasb.org/srt-types/2025" xmlns:MODD="http://modularmedical.com/20250922" elementFormDefault="qualified" targetNamespace="http://modularmedical.com/20250922">
    <annotation>
      <appinfo>
        <link:roleType roleURI="http://modularmedical.com/role/Cover" id="Cover">
          <link:definition>00000001 - Document - Cover</link:definition>
          <link:usedOn>link:presentationLink</link:usedOn>
          <link:usedOn>link:calculationLink</link:usedOn>
          <link:usedOn>link:definitionLink</link:usedOn>
        </link:roleType>
        <link:linkbaseRef xlink:type="simple" xlink:href="modd-20250922_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
        <link:linkbaseRef xlink:type="simple" xlink:href="modd-20250922_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd" />
    <import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd" />
    <import namespace="http://fasb.org/us-types/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2025" schemaLocation="https://xbrl.sec.gov/country/2025/country-2025.xsd" />
    <import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd" />
    <import namespace="http://fasb.org/srt-types/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>6
<FILENAME>modd-20250922_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>7
<FILENAME>modd-20250922_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 6.2a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="modd-20250922.xsd#Cover" roleURI="http://modularmedical.com/role/Cover" />
    <link:presentationLink xlink:type="extended" xlink:role="http://modularmedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>9
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.2</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Sep. 22, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Sep. 22,  2025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-41277<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MODULAR MEDICAL, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001074871<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">87-0620495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">NV<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10740 Thornmint Road<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Diego<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">92127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">800-3500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">MODD<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="ea0258326-8k_modular.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://modularmedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" isUsgaap="true" original="ea0258326-8k_modular.htm">ea0258326-8k_modular.htm</File>
    <File>modd-20250922.xsd</File>
    <File>modd-20250922_lab.xml</File>
    <File>modd-20250922_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "ea0258326-8k_modular.htm": {
   "nsprefix": "MODD",
   "nsuri": "http://modularmedical.com/20250922",
   "dts": {
    "inline": {
     "local": [
      "ea0258326-8k_modular.htm"
     ]
    },
    "schema": {
     "local": [
      "modd-20250922.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "modd-20250922_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "modd-20250922_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2025": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 59,
   "unitCount": 3,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2025": 22
   },
   "report": {
    "R1": {
     "role": "http://modularmedical.com/role/Cover",
     "longName": "00000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "AsOf2025-09-22",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0258326-8k_modular.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "AsOf2025-09-22",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "ea0258326-8k_modular.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentDescription": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentDescription",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Description",
        "documentation": "Description of changes contained within amended document."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AnnualInformationForm": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AnnualInformationForm",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Annual Information Form",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_AuditedAnnualFinancialStatements": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditedAnnualFinancialStatements",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Audited Annual Financial Statements",
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CountryRegion",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAccountingStandard": {
     "xbrltype": "accountingStandardItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAccountingStandard",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Accounting Standard",
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodStartDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodStartDate",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period Start Date",
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentQuarterlyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentQuarterlyReport",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Quarterly Report",
        "documentation": "Boolean flag that is true only for a form used as an quarterly report."
       }
      }
     },
     "auth_ref": [
      "r12"
     ]
    },
    "dei_DocumentRegistrationStatement": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentRegistrationStatement",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Registration Statement",
        "documentation": "Boolean flag that is true only for a form used as a registration statement."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentShellCompanyEventDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyEventDate",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Event Date",
        "documentation": "Date of event requiring a shell company report."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentShellCompanyReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentShellCompanyReport",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Shell Company Report",
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine3": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine3",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Three",
        "documentation": "Address Line 3 such as an Office Park"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Bankruptcy Proceedings, Reporting Current",
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Elected Not To Use the Extended Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r19"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "dei_EntityPrimarySicNumber": {
     "xbrltype": "sicNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPrimarySicNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Primary SIC Number",
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity."
       }
      }
     },
     "auth_ref": [
      "r14"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "dei_Extension": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Extension",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Extension",
        "documentation": "Extension number for local phone number."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_NoTradingSymbolFlag": {
     "xbrltype": "trueItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "NoTradingSymbolFlag",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "No Trading Symbol Flag",
        "documentation": "Boolean flag that is true only for a security having no trading symbol."
       }
      }
     },
     "auth_ref": []
    },
    "dei_OtherReportingStandardItemNumber": {
     "xbrltype": "otherReportingStandardItemNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "OtherReportingStandardItemNumber",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Reporting Standard Item Number",
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS."
       }
      }
     },
     "auth_ref": [
      "r13"
     ]
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_Security12gTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12gTitle",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of 12(g) Security",
        "documentation": "Title of a 12(g) registered security."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_SecurityReportingObligation": {
     "xbrltype": "securityReportingObligationItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityReportingObligation",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Reporting Obligation",
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://modularmedical.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "g"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12, 13, 15d"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-Q",
   "Number": "240",
   "Section": "308",
   "Subsection": "a"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001213900-25-090336-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001213900-25-090336-xbrl.zip
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MZF0Z@7YT"?69?\Z&N_D]?CI$A!251A%TB)C&;OZ ZKZ"_U7RQ(9! RUF;B6
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M5 @SF(#POEY4-C2EVLB. 4!F\(?W'-2G6@\QXQA\GD+0Z9'W$'-RPQ11Z<[
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MT5(+T((*M^<QFHV/;O_=Q?[>IP-C<_!\?"0J='&:X,)KFQEX6%_!N!9P?>2
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M*'"+9A]J? NX"]P%3V'K .!R/1@"+GT"X0,-"@^?T3$IOLM)UMK&=C]9YK?
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M.;%9H"E!9L1:%;"Y<O6 <X:(KHF1Y.A[2N-7)]*/(V@OE(&)=@T.I; !,X2
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MA-8UA^TPSF"GII!-P.<2B"&=::M[E:8YK'OEP#*W@P= [?:N+PBXVPF,VH#
M]!*\^A*-GEO#.NW"#/7:_5.L' \[SP$/OTH)1!NP*U?:9EH(-@U&-KG47K>Y
M6IOG%(WF3F_SI?&,:.:?64RZD,V!H&!)Q\"; 6\AZ4%R:I L%<E\*ZMPMUZ[
MYA&4(',J4Z(3GQ)Q'3'@# U$AKET[^9?JFT3:AWC^%!W.M;A1-5K%8'J5*^2
MU"CJZUF9"68#RERI+"=H591+$LS:(3.7P5PD 0?($K\=+*S7 @MRRH!<ZGG=
MM;-[#ER%2,]I4WH[ Y(W@*7KG3S]%4A8+S!50GMW>[N!H4;!,T+0==W8Q<U3
M?M[/9'8NURU+34(B268*8Y"YA' 5^65A 3:%S)?!/F< V"!RI_4JAYZY\/(H
M:_.PM'9\_B[_,QMGMJ<Q9ZFY.>>I3V5C"!G3J8AFP,,MQH'KQ&5HXL@B;7NF
MY[%M#KXEV4 -#<%;W A8B6F0H)M'#)AN2!# K1Y%>NMAT"<I7+X!=N2%AGA2
M0T_Q7M$&.V0&59,B$REB4BG :$R311#.=V,Q0]=KWP%3;I5R=#DGIY+%/(OS
ME S)EBSDV$KX1@HS_@T<>$YT; 6 E8:XXNBE;C/ N'F5HFQQX*/36"]3F/+B
M&)>$NPB&IDHDQI0 ++!])G!] "[ RVTG?5Z9Q?Y](E5R2_QM<Y/\R%D4[I%S
MV,1]F.-SAJ4KJ$(V-UV_M3LX_MGK66S%M#L5O9BW>&TL)(1H?NT0*L%/I-U$
M796(> @J?,7*B^L+&/+O![6&BJ;O;L%:*I8U!N?ZM#EFX%:P]M38HBCZ;85H
M7'YQ(86-63IEP>!;:'%KY&?BDT_(=@H9-R]R7(Z6#,!(83%M@/+:X[$IDQS3
MUJ#3LLQ]397-\U@2WF+: /SP0,.(IGGAAQA7KZ$""+/(F? )GP"!DX,PK@V6
M70'\"^DR((KP#06 N0LH^R$5MC&1MR'UVH1N/[?=YQOWN>,^W[K/=^[S_09P
M+OQAUUUH(R60]L?M#;OB"H*P2KA[#IZU0L<",/(TU;G1V; /&QQHV_%QUI17
M4'_"A1YVKQJ.6T@6,$.7R83?P"Y/F&T\O6FU&BW(J+;'D[)$83;B\1C(#?-M
M74.W(/GNF&<;F+NH#".F<L=SS0KX#=)EP%A82/MW\J+*,M(Y=>5R8,FF/^E6
M#;#,(,<BN>8)\B1#MH$^H(Q(8([%)CJ2-6Q8@\))-+-9NR+F["4@8.'<P%AX
M8-\MII^,F2'/V^A!Z]1K8%A,]DEH6;Z0\Y9D^5&@%5>F68*:)<)PA"S!9HNI
M#M!:.)N:BBS"[HNMFV5FNI*&USU9SRUO$3^33O72 $G"4K4TW\YY<\K?PZ8;
M;JLA\ZZ"O-=;M;ADV !US!7B2MA?G>O6:WYX:%L-OJW@.RJN=>>5H)$ /S'"
M\').C-W<BU%1Z%O<5_F8VH'=!"Y&V[O-W=U7Y%9ELZ1L$IDV9D,OAA4(TS@R
MI857495*JU-ZPV.@W<=^ 3V#!WGQ9K2!] /T:D[\;99YN[VS'N;%HNNA62U.
MJ?S$=)EBX[:%+(@@51FJ;MI,=V_:0E>K7EOL7L+R4*R3A0 !3$IB#?9%@F]U
M13G" ?HE^IGIO"$RFC'.8/7:@L6>%]E_(B6.)V0F,E=:)E & [=7B)+*91[?
M)_'XK@JE9W4/)8T8-759HB%Q&*"%W1O.7+?[A\2_,U(Y&6D"0#=)09=Z#1W0
M!GRNT2W1I?#67H-Y2?E#;-^*;\;VK;B9YF77'U;<=?;)Q]38?0]U<1VG??(S
MC3*\_7]4^Q7-X VP3T:S%-;9DW3,@WU RYA9(YT)7'JG5*?Y47CGI8;\JK[&
M%Y[TR&G-U[*:RN;P_:P&&"KP7FV:8IX]:MA5;;EC4#C_!*,UC]P+.ZP^L0V+
M;3.%X&JAC"MDV*;':3A,W[;=R05+A<0$27[$AN3[S7\B-YYPJ$A*P)RKLQ37
M_E"[?ON!GX=HZN C$%%$4P6!Y']:..&#&CS\C(\]E8,!=/L0S_9[$#?D$.&P
M<;.&.U53]63GU=P*2Q]ZVRH_98[G?(.V%3/><^F;9T0\+/;K;0#=HT$.@_?B
M_Y_;..6VLN.;>R_&,;+N/6[P8B?K1+V\ CW*7]4;4[T8R,@:YF^7 (=ZF9X*
M:<YOV>M"SE[PZ1[PGANM7LNM]H)35M:(ZVBI:[T8R<H: #P]JBTJSRSG5'5Y
M/5UX!'M:"\<*\D, (8OXE7WO(]S[_R@2UTBN![_T^J07F'-G]=J9Z>-5'$5>
MKLL7L=\[..W#B?%CL=_6G:3VOGW-]7ISMYPEL_T)HV)%,?#'J/;G-T:.$951
M^6@A^[P*UOY'U/'L^[7.VD'/M->Q(X%O]_!4<;@4I+]U?TL3/ZXKE:8BIQ\'
M/YWT+LCIT>"XWSMID..S?O/1IBYCU,Z#@.Q!3ZV\%W!8)B?/!GE,![4DG?R#
M8M@<-<DA4VHY.U\-E2O/W9]R-L'"*LC,L3QSE/Q^%>[X"M5JOZI6^56P>0?U
M2;M\J_Q"YTK/NK7?616KW@6L^M7+W7,]Y W+]LO+%/<R9?LO^3+E&7GKX4'W
MIX.C?WTX/CP>D5YWZZ='^.+VZK\LZA?E?[EC>>8M2OG,[Q-I\J1F^/>0S;^H
M\Y^_H@6>;O(W3[#:TCH+.(;G@38]EA4QM?P-^<(-5'53\=_QV'<AZQB@O8-+
M(HRZ?XLP6IK_R3R Y*;9PO\3Q/ [\W^)_ ]02P,$%     @ TT,W6S\",,HJ
M20  Z'\! !P   !E83 R-3@S,C8P,65X-"TQ7VUO9'5L87(N:'1M[7U[<]O6
MM>__G.%WP/5I.^(=6I$?21K;]8Q>3G2N+?E(<M).IW,&)$ ),0BP "A9_?1W
M/?<+ $7%DF/'ZDQ;BP2Q7VNOYV^M]>*GTS>O7PX'+W[:W]Z#_X_P/R].#TY?
M[[]\\0W_/WS[C7S]8N=H[Q_1R>D_7N__[<&L+)IGT:.M11.=9O.TC@[3R^BX
MG,?%F#\81R=IE<T>P _AIV]O^KOGT3RNSK+B85,NGD7PN/E@4C9-.9?/FO1#
M\S#.L[/B651E9^?-@Y<O=E[N?SC/)ED3/=U\].*;'5C+VT\WBU^7=9/-KAZ\
M_$LQJ1?/?Y^Q#_</3G_:/XY.?SHXB4[V=]\='YS^(SH\PD_V]8.#_9/AX!5\
M]LM/![L_!<_"O_?_OG^\>W"RO?-Z/_II^^?]:&=__S ZWO_QX.1T_WA_+_H%
M!@E>&&T?[L$/=W_:/OQQ/]H]>O/FX.3DX.@P:@WM??EJ.-@^1-K:/MV/#G"0
MUP?;A[O[T;NW\/7V(<[ES=M3?/;5\=$;F<3Q-GWR[G!OO_7V[=U3>&WTZ(<G
M3\;1-OS]9A\>VXLV\+F_Y,F_E^5S__&_5/3A:(QSV8,?[>X>'>\='/[X^A_C
MZ,TV;M\I; &\]16M'E9T<O2:5KO_]C1Z^^[XY-WVX6ET>D03AJ=V3P]@U[RY
MT@IA*J<K9GULWC4<\,NV?]X^>$WGX._#&!^&[=J.X/V')_!K_ ;G>?)NY[]A
M?)C,F,;P)G&\_S_O#HYI&B>X21V3P&/$%],>X$D,!W3:VV_?OC[8I:GP83F_
M>[W]R\EF0$;XGN#U<.;OZ 5TMD)D^SP/]Z>XY;#=;U_O[_VX3[/9/3H\W*<U
MZFRBG:/#[>C5P=X^/'[\H\SXW2'MXA%=@=='L('T4GC)#M#8.Z!U.YW-O@LZ
M*?/D;F[I-"V:M+J.0=S]^'@!B22/=O\?DAQ<6CB'7[:/CXGTWASMO7N]?1R]
MV=^#$W\]AA/8_7QVZY1(:'?_]>NWVWMX2__V8.L!_7WR=GM7_Y8Y3LHJ2:N'
MTS+/XT6=PDOE7\^C];GQ998TY_CHUI]1J+TX/=;77Z15DTWC7*<,B_/7D*>S
MY@$)V!>G>_HK>=^3)_"Z7^*JBHLF.CF/J[1^%OWS+__UPW??__#\7R"&]_I^
M^/3/=E?:3[4DHUD!C7A0U\LTVHN;]-EP8(8S_QA'C[<>?TOOA?\Y)C6 MIQV
M_PX%VFW(35IZ5B0I_F!K\]NL^!A92ES)O2O#07A9HHWF/%6I\N*='N>+;]Z]
M5*D"= Q$,LM@WLUYW(R!\*KH(L[A$*ITFF87:3*VQQ[!EUE31W%=PV3J\/T_
MP6U+*_?UPT%61[#>K,GQ1<M%643X&[@Z<WA-D43U<O)K.FV ..F+/)MG3=QD
M);P=GDT_I-4TJU-Z%+^?ED62\=?G:95F13R#=T5UVN#,F_-Q%#?P\%74P-;C
M&V#&],AP@#]/@+#HA^4LG/Q! >^-\VA?AT0B]+8*Y\!O7%09_"],^=MG6UO1
M8G.^&6W@L?^CK-Y'NUG#PX_P:;MWEHB'@\=;3[;""9S"GL!Z<''ML2?+)BK*
M!O>@2FE!8QP?=J^>5MDDI7/#"2Z6U?0\ANG/JG(>O2F391Y7T9LT04X S+*8
M;L(> 9%>Q$D\'$S+:E%6/&@PG]UROH"==*<QAA6E48W<(-J(:_?PX@0I<PYG
M3?N[!#+'*7;1G[ 3GT[@0&# .4SCI"FG[T%@PT_-8F##IW"<,V?\X <1C0@#
M L'I./!@GD>P.>F_EW"R0F+F@-_B2V$SZBA)9UF1)E%6# <GL"#<C<<;DU&O
M7/G<5?3;935P=+HKC_#4-F%2[U[NX:;Q7:0/@;: "OAVZE[S/=?M3?,ZO43J
M@(WV3HK9#AX6G/BBK&%I<+S^$_BZ&<C'\C(KSOC%P\%Y?)'2-_,T+N#SVG("
M,X:9^K,[/LU;M*U0,M_DX!Z\_*C%W2ZYV N_/9ME>>;SLN$ SZHF)OTVK6J2
M""AYD@PD3I-?D9 IS%_->54NS\[IYL,W\Y+(!\\?>%I<9;@,D I-5>8U_;36
M/T'D1),K^8S9PY0YACPP'%QF0"BQSH,XVO1<I1,,M*R)*Q!GA1_53;6$#_A=
MQ\L\C9YN?6LX3XJDMJS@ L!>;T^;>^X1D,/.L@8^4,.]W8M=N1)9BDCB*Q#Z
MTW3!4OPD;I85?#;FOV"G]=_XX.5Y!J<%AQM'LQ3. 'A\GI[!_YZ7>88/9*QM
MO ,V!<=V HI%2C0B+P"I4\A+)G'Q'OE*!F><-4O6,.3G]#MD2$;$(VG$R^:\
MK++_P(OAC16(&*!8(K@\OL2/2I35T5D):GB!<A'F%4^5.4YSX')W32"?+2V@
MX,Y ARP+GP*".X2W;O\#: #%63H<V!]]M?O&6IG1>=I7"#=0]+:_5#5^4:..
M1S^I\2?C:!&K@O^GK<VMK4?1 O5G5*GN^57G7H-*2 KF/MQPV#@8I.[F7;6E
M7-)>S%$(C[DLEWFBUA!]?TX&$ROU^!-0HZ?$1SPKQIO&&+C2-%\FP*S&$8JO
M$BP#:S4)<TPG(% 753I+*V1*<O1D;X,.O^ G+T5--KPJ(P%'.CR*9.*LSCQ
M ))+89+#;0017.(OQ4*+X4/^DZ\K_0UZV-B\_1)5;EE\W;-Z,3G'OBGP%=]V
MR_U G^B^[@Z_U*=1^4 2?/3#DZ=DW\1PI@D:X&I&5\M<^&N5GH&%R/)N 2;C
M,C^+45@VQHJ[9PO!H;"VV*G2DN)ZD25H;I:H;AKKFAAO4\!/S[,%6#,5O)?N
MLCS":L2R\#Z)Z[J<9O+[7TNX<]$%K&99P16A.P_/@'X] 26[N4+E%KG->#C@
M1^G6FT\=323:(!THBL_28DH*,ACR..\Z8_\,WL>1Y0MT:Z^0HI 7@)Z4?!1-
MW/*Y>'1RIT[ /O-8]^+_/'P8O<K2/'D6O86]?0ZO_O<2MCB%&40/'THH\\7>
MP<\Z/7?01X\[1OT./Q,_L7ZVD\=PKH\VOX5%U:CIPA1^ZS%XWNP;L\L7W\!:
M.I8UJ=+X_<-)"@( UKZ@O7!?_5W'JW'Y[D+XZ]5#.AO^#>XX;_(]IU).A2;J
M</#HZ=.VZ"#K%;[QF/[D2M46T;31'U,O44D0AXYOX8Z-R4ROFX/)-4E5VK =
M#V0%>@B\?#@@CR1I$O@R^/^QVF(U\#)T4Z)88FM*A5)D_)U1G(#BTCG)\_@"
M;3=TAC8PURS.<WZFAJFH2XFD73J;I=-F.-!IXX#W\BV@&GO&ZZD=5MMX\OEK
M&Y_SQI]6,>KU4;=WA%P>QF$!.S8<+"I0%[(%*!OZTS=Q]3XES;U<I 6Y51O^
MZI[,NW=[.. ]ZR;SP[A.XG]'/^;E!'99=E>XEAAYUBD]IZ]KUPZJO1/S(Q89
M#5& !E<3?X2?P>AX'9QCBR1B1I&KK( GTAKOSS-W>KOQ(FO,_,8K9][^[B3-
M,8C#CPP'&\J4E]-I"@IH59-AZBX8KC%HF&<?%Q^Y2S7P,YB/2V=%/<,(Y#;H
MVQUTMEOF98&A1R8+?5Z]!QJT(U]U.9ME<"I17D[90FBB[__Z="LZB;[?VHKV
M83' 9N$G[YKX/((OOM]B-NP=Z'#0Z!AH C2!N^(/=:IKB00GP/688UED>W.<
MD#[XZJ12/'+W@.*S#GQ@TT91A79,J):<3#5(>E#[:C0K1&-SXK*B)\[C)$43
M&/ACR7H?_!NMY""(7]'_(R<E'LG:(([9&;)WPO1L@-"C87 =YY2D>08F\97J
MMNJM0SLW2I8Y1B) RR&&'$])1T4GV.**IO%V[Q7]@6HG6.*RSO3A/,YR,K#E
MGW'3Q--S-+M'NE>'92/A;#-S"37 ?.>P@ (&3DCUA:D%8?GVC]U ^N9P\ OP
M"7E=&E=Y!IN%:(=L1"&TC4>CR-$S:+<V,O@2GR^6\PD_[CQ2DPNARFJ*NW(\
MI$CB*@'":YH\)8_"6Z#!,B%0@$1[T448V6!Z,L(9,&9CY 9R5;;!H!;M >H.
M'ET=9PE+,X:62$1?#HZ^B,_.0!KA"_RX/LM05))\U$%4+](I EX2W?-XL<BS
M*3DL.PX&SO02';*&8Z);)Z[/85O5PQY-SU/@VTD57Q9(>7$0<,+8TG"P+$ )
M9J4"?T]_F 6#+CQ-DR6,XTW/;M]T!-0,6X9*P\U6L F?P8/O'Y9P,^$*Y,-!
MQS(-5$(#6>.H*'6_\5+,TP3^B9,Y6\:XGVE*5,X>HN9J0>^SW\%71=G$5?8?
MNG0C]1Z9L8<#N\=V6)QM@Y(.+3FB0/@1TO.9T(Y>5@KAQM55!WD@3L9Y)?YB
M<7Y5(P FQ^M:56D+*P(BT6<"2[ C<_?=P-P,DTL(JR"W.:"O^ )N/9V%L6F,
M(:2/XKLF:6KQ3724LV6>C^G:L,((9))V+*][ 2$3FQ&=%M,T%T/Z4ME"A2?W
M9.1?<5D+WT29 $.F9D@SG2RKUHO(>^QJ$-%;8./(FG6!+4 ''$^]S!N.N9J-
MK9GY+LJ*YLRSPK-![=9RIS6VG/?*X$/B)<@[V(BIN #P+7"=@&L)#RJ7C2&Y
MOH' X.)Y!F,10 #,WA*(QL<:.3>S=_:&J!CS)&>M)*/GR>L!B5(T,<*4JG1:
M5@DP@W/+1Z\?PKQ662YY0<SN\PS\(979DF0DN)>$L.&#3E8BA-8E;. Q"O$L
M&C-V02\ A6OG9;!Z')"!ABE< ^##\11Q 4C3+730<!!/WQ?E99XF9ZP!Q&=(
MYXPL@=]6:5P;@D)VR\YN2Y:@=\!/XL7Y.!!.1K'IH,QPGRWRC>_.&A2+]]0,
MX7 ,5H#.8.L+5H-$:1(A$@OG9YJK&PX@B!(13Q7DN/DEYYG<KD(["11:TA)8
MET7"<T0Q$K0)BM\(9_BGK<V_/KT.%1DJ=!U3,MK<EWIT=QM,>?P\.J(8=OT,
MIR!:TO/H9X0UP-=_H%B+NPVZ <^C4U"WGD7;53S)IL^CPWB>\B:!I@=+?^S%
M1?17^,U]S.9SY4Y3XDZ[8AA8W5B0M3,4" 2H)8O8,944/,&PVAKDJ6@X(#G0
MW9[5C<"[24@0*^*/2?<9JTL01"+:%<V2X9,QFW"-*-WTXL876ZR:HI&6ISWR
M4$(U+-3'[.UL>0+BO"X)I*VZ<.@3 +5+G0(,S\0]F%R)]XS$LG#3EF&ECK;,
M=<)ZVO3$@%(2!X$"KVS)[N% 5N5I>.BQS<B'-N%-(\\"8@!0@?CGQO;#G5&T
M\??1O_#SC>W1."($]#,W8/U[DK[,X$9Y2[<\2R^#Z2;Y2V9)N( P#VDK*U":
M8*90^SN^KNU<*#B@Z&_AC[K]8W!)K7;_C/PK2 \__[+]5A4Q5_7-YH17;E(P
M01=(94GH_;C>%Y&)SMS^BO)L4-N&C3VW;BM4A*V-YL9RK6<A'BD/(=<%!ID4
M_$57WE?@07MYO'(4LI&N'\9]J<FF(3MLD184]ICII>:8H0V(G)<P@%[L#2][
M@\/0WVUM;4PXI>38!I(/WYQX(4>+VE;LL(/?R^/+FM)W:+^=R8[962;<F)%T
M>GC*YM*,?"(;5R.V7N^2)/! _L.4MY,EXOJR[GRCMA+4F?E\3\@P)I\MF#?,
MPG;RLD0&>!:]WGR[&6TX*&[]QD^.,CX$%5%V2XRCC$DF(T?NQQ$\DJ<AP&1)
M9OPZ]!(2'UQBH%[/E:&.DLN2:)U^[N1= 0$H %.=1-Z3UCU-&.\V(5/TY?J9
MC:Z_KSB7K(/OK$T^P#9FWB]6[';<<ANO>/B&;&@X<-=U[0[V'FUX6S4#E7)%
MW4S1WU79O)>U+&M!,?I;M):P;:?MM?/#,&9 UK9$3HB_/Z?[_8FIX/[ >P[\
M[S<Z\%[G&:DG#*:?(+<!;H+LC9*+4S=@Z9D:Z*2=HL^4'(@43+<9BJV'A14:
M,^L2S2O?YD!CPSX 1A8%0M S%YL(SW"@#VS^WD3XNYNX!VUW>ESQ^;'R1CL>
MMZ-C;&BB#4A)0;V.WJXC5KGY!.3+Q@\F AO &-E;&P8*R3YLXO>IRM4I?!%/
MT7"&)4WKP.C%D [*'<>.56\[9CK@5PN.DO88RRFAD60_Q-W;P'+%LUOVOLH2
MKN_ IZUA-1Y_C2O!CQ=ES4FZ&D/C=SNILAAO_&)]CW>6O:CZ=1OY+_G+E%78
M*+V2F$K2AI '%K<ZRZK:(&YLJ&&:Q\M:F1LI;5AP [6BK*W-!]"Q""$] AWS
MU$@7#S:!Z2_ZS .-EK/R[L#,*,9+W#A%(FT<0P67.@KL&@73K8UZBRSHK=<
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M0PYQ&9TY2>$($E-#TQ20L=4T82\H%6*2PDFFO -2?HDQ^: M]K E8N?PCX5
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MK%+-E+A$8KFLT/R$[2@,_ZO,)MU3#U//!1$/[EM:U!(/Q;N[L[QZ>$ )Y*^
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MOY%.5J^)"7M<V:ZCB)E8<=N4%3B5U_QP*E<<7$E=G:R!C0OBR^1AX*E.4IY
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MMH>S0:479-I6K< <9.'ATO+6!XL,D.L9&>(3DV)A=<OO.'M): 0OF2&Y%V
MTU9J#&UXZ-@-]O%3+8AUG->Q1BW*>[\D6N9GE&F:M \Q2A,>)$UCO8.+4OM$
MXHYE.4[_G3QWGHC;Q5[PL!JV0M)0AH>*S5X?,"H&B2 ?)]8EKO*&AO55,J/<
MW2O %EN'5X!KA4% 8'/4?@5873U1(M?=+!GE! ,C0K/862=;3%5]7"L+HXO;
MAEH]7'ROA<;'%UEF=TGO'AF%'Q!H2USU-&1.][99'D2/ Z;,7B]DJ-!YNAHO
M,TQD]N&[5N9L9C?M5!.Y+@BB=TTWK6E:ESONS=]XDHL]S]AFLZ7E71[;<X.
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MZV\#H]TR\Z8F-6D:%!H09V_Q"Q!XJ +5ZOA0F[%\7LR3#XW+;&XL>EH\8G$
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MS;,[O]M3"YS]3A,@_C]?"_XCMT@9N*>*R<2>TA6 _9$82/T<D[K'(2KO&Y%
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M.&M?;6]D=6QA<BYH=&U02P$"% ,4    " #30S=;$?2)22$1   BD   '0
M            @ $U&0  96$P,C4X,S(V,#%E>#$P+3%?;6]D=6QA<BYH=&U0
M2P$"% ,4    " #30S=;LWK>HX ,  !21   '0              @ &1*@
M96$P,C4X,S(V,#%E>#$P+3)?;6]D=6QA<BYH=&U02P$"% ,4    " #30S=;
M/P(PRBI)  #H?P$ '               @ %,-P  96$P,C4X,S(V,#%E>#0M
M,5]M;V1U;&%R+FAT;5!+ 0(4 Q0    ( --#-UNBS"*$*@,  /0+   1
M          "  ;"   !M;V1D+3(P,C4P.3(R+GAS9%!+ 0(4 Q0    ( --#
M-UNLK$&R_ H  '^&   5              "  0F$  !M;V1D+3(P,C4P.3(R
M7VQA8BYX;6Q02P$"% ,4    " #30S=;%B$Y'5P'  #@5P  %0
M    @ $XCP  ;6]D9"TR,#(U,#DR,E]P<F4N>&UL4$L%!@     '  < ZP$
' ,>6      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>ea0258326-8k_modular_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="modd-20250922.xsd" xlink:type="simple"/>
    <context id="AsOf2025-09-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001074871</identifier>
        </entity>
        <period>
            <startDate>2025-09-22</startDate>
            <endDate>2025-09-22</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag contextRef="AsOf2025-09-22" id="Fact000003">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="AsOf2025-09-22" id="Fact000004">0001074871</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="AsOf2025-09-22" id="Fact000009">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="AsOf2025-09-22" id="Fact000010">2025-09-22</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="AsOf2025-09-22" id="Fact000011">MODULAR MEDICAL, INC.</dei:EntityRegistrantName>
    <dei:EntityFileNumber contextRef="AsOf2025-09-22" id="Fact000012">001-41277</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="AsOf2025-09-22" id="Fact000013">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="AsOf2025-09-22" id="Fact000014">87-0620495</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="AsOf2025-09-22" id="Fact000015">10740 Thornmint Road</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="AsOf2025-09-22" id="Fact000016">San Diego</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="AsOf2025-09-22" id="Fact000017">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="AsOf2025-09-22" id="Fact000018">92127</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="AsOf2025-09-22" id="Fact000019">858</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="AsOf2025-09-22" id="Fact000020">800-3500</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="AsOf2025-09-22" id="Fact000021">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="AsOf2025-09-22" id="Fact000022">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="AsOf2025-09-22" id="Fact000023">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="AsOf2025-09-22" id="Fact000024">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="AsOf2025-09-22" id="Fact000025">Common Stock</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="AsOf2025-09-22" id="Fact000026">MODD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="AsOf2025-09-22" id="Fact000027">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="AsOf2025-09-22" id="Fact000028">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
